<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">FEBS Lett</journal-id><journal-id journal-id-type="iso-abbrev">FEBS Lett</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1873-3468</journal-id><journal-id journal-id-type="publisher-id">FEB2</journal-id><journal-title-group><journal-title>Febs Letters</journal-title></journal-title-group><issn pub-type="ppub">0014-5793</issn><issn pub-type="epub">1873-3468</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7267562</article-id><article-id pub-id-type="doi">10.1002/1873-3468.13806</article-id><article-id pub-id-type="publisher-id">FEB213806</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>Knowledge&#x02010;based structural models of SARS&#x02010;CoV&#x02010;2 proteins and their complexes with potential drugs</article-title><alt-title alt-title-type="right-running-head">SARS&#x02010;CoV&#x02010;2 protein models</alt-title><alt-title alt-title-type="left-running-head">A. Hijikata <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="feb213806-cr-0001" contrib-type="author"><name><surname>Hijikata</surname><given-names>Atsushi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4297-8368</contrib-id><xref ref-type="aff" rid="feb213806-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="feb213806-cr-0002" contrib-type="author"><name><surname>Shionyu&#x02010;Mitsuyama</surname><given-names>Clara</given-names></name><xref ref-type="aff" rid="feb213806-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="feb213806-cr-0003" contrib-type="author"><name><surname>Nakae</surname><given-names>Setsu</given-names></name><xref ref-type="aff" rid="feb213806-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="feb213806-cr-0004" contrib-type="author"><name><surname>Shionyu</surname><given-names>Masafumi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0431-3456</contrib-id><xref ref-type="aff" rid="feb213806-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="feb213806-cr-0005" contrib-type="author"><name><surname>Ota</surname><given-names>Motonori</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9090-668X</contrib-id><xref ref-type="aff" rid="feb213806-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="feb213806-cr-0006" contrib-type="author"><name><surname>Kanaya</surname><given-names>Shigehiko</given-names></name><xref ref-type="aff" rid="feb213806-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="feb213806-cr-0007" contrib-type="author" corresp="yes"><name><surname>Shirai</surname><given-names>Tsuyoshi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2506-5738</contrib-id><xref ref-type="aff" rid="feb213806-aff-0001">
<sup>1</sup>
</xref><address><email>t_shirai@nagahama-i-bio.ac.jp</email></address></contrib></contrib-group><aff id="feb213806-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Faculty of Bioscience</named-content>
<institution>Nagahama Institute of Bio&#x02010;Science and Technology</institution>
<country country="JP">Japan</country>
</aff><aff id="feb213806-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Complex Systems Science</named-content>
<named-content content-type="organisation-division">Graduate School of Informatics</named-content>
<institution>Nagoya University</institution>
<country country="JP">Japan</country>
</aff><aff id="feb213806-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Computational Biology Laboratory</named-content>
<named-content content-type="organisation-division">Division of Information Science</named-content>
<named-content content-type="organisation-division">Graduate School of Science and Technology</named-content>
<institution>Nara Institute of Science and Technology (NAIST)</institution>
<city>Ikoma</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Tsuyoshi Shirai, Faculty of Bioscience, Nagahama Institute of Bio&#x02010;Science and Technology, 1266, Tamura&#x02010;cho, Nagahama, Shiga, 526&#x02010;0829, Japan<break/>
Tel: +81 749 64 811<break/>
Email: <email>t_shirai@nagahama-i-bio.ac.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>5</month><year>2020</year></pub-date><elocation-id>10.1002/1873-3468.13806</elocation-id><history><date date-type="received"><day>25</day><month>3</month><year>2020</year></date><date date-type="rev-recd"><day>27</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>29</day><month>4</month><year>2020</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 Federation of European Biochemical Societies <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2020 Federation of European Biochemical Societies</copyright-statement><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:FEB2-9999-na.pdf"/><abstract id="feb213806-abs-0001"><p>The World Health Organization (WHO) has declared the coronavirus disease 2019 (COVID&#x02010;19) caused by the novel coronavirus SARS&#x02010;CoV&#x02010;2 a pandemic. There is, however, no confirmed anti&#x02010;COVID&#x02010;19 therapeutic currently. In order to assist structure&#x02010;based discovery efforts for repurposing drugs against this disease, we constructed knowledge&#x02010;based models of SARS&#x02010;CoV&#x02010;2 proteins and compared the ligand molecules in the template structures with approved/experimental drugs and components of natural medicines. Our theoretical models suggest several drugs, such as carfilzomib, sinefungin, tecadenoson, and trabodenoson, that could be further investigated for their potential for treating COVID&#x02010;19.</p></abstract><abstract abstract-type="graphical" id="feb213806-abs-0002"><p>
<boxed-text position="anchor" content-type="graphic" id="feb213806-blkfxd-0001" orientation="portrait"><graphic xlink:href="FEB2-9999-na-g004.jpg" position="anchor" id="nlm-graphic-1" orientation="portrait"/></boxed-text>
</p></abstract><kwd-group><kwd id="feb213806-kwd-0001">coronavirus</kwd><kwd id="feb213806-kwd-0002">COVID&#x02010;19</kwd><kwd id="feb213806-kwd-0003">crude drug</kwd><kwd id="feb213806-kwd-0004">drug repurposing</kwd><kwd id="feb213806-kwd-0005">homology modeling</kwd><kwd id="feb213806-kwd-0006">SARS&#x02010;CoV</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Japan Agency for Medical Research and Development </institution><institution-id institution-id-type="open-funder-registry">10.13039/100009619</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="14"/><word-count count="22184"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.3 mode:remove_FC converted:03.06.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="feb213806-ntgp-0001"><fn id="feb213806-note-0001"><p>Edited by John Briggs</p></fn></fn-group></notes></front><body id="feb213806-body-0001"><sec id="feb213806-sec-0001"><title>Abbreviations</title><p>ACE2, angiotensin I&#x02010;converting enzyme 2</p><p>MERS, Middle East respiratory syndrome</p><p>RBD, receptor&#x02010;binding domain</p><p>SARS&#x02010;CoV, severe acute respiratory syndrome coronavirus</p><p>SBDR, structure&#x02010;based drug repositioning</p><p>WHO, World Health Organization</p></sec><sec id="feb213806-sec-0002"><p>The newly identified coronavirus (SARS&#x02010;CoV&#x02010;2) causes severe pneumonia (coronavirus disease 2019&#x02014;COVID&#x02010;19) and has rapidly spread across the world from the initial outbreak point in Wuhan, China, in late 2019 [<xref rid="feb213806-bib-0001" ref-type="ref">1</xref>]. It has become a global health emergency, and on March 11, 2020, the World Health Organization (WHO) declared a pandemic status of this novel coronavirus outbreak. Since no approved drug that is specifically targeted to this virus exists at this point in time, drug repositioning/repurposing is thought to be the most effective and feasible approach toward this clear and present threat, and researchers have initiated studies by employing various means in order to find potential therapeutics [<xref rid="feb213806-bib-0003" ref-type="ref">3</xref>, <xref rid="feb213806-bib-0004" ref-type="ref">4</xref>, <xref rid="feb213806-bib-0005" ref-type="ref">5</xref>, <xref rid="feb213806-bib-0006" ref-type="ref">6</xref>, <xref rid="feb213806-bib-0007" ref-type="ref">7</xref>, <xref rid="feb213806-bib-0008" ref-type="ref">8</xref>, <xref rid="feb213806-bib-0009" ref-type="ref">9</xref>, <xref rid="feb213806-bib-0010" ref-type="ref">10</xref>, <xref rid="feb213806-bib-0011" ref-type="ref">11</xref>].</p><p>The SARS&#x02010;CoV&#x02010;2 genome is very close to that of the severe acute respiratory syndrome coronavirus (SARS&#x02010;CoV) [<xref rid="feb213806-bib-0001" ref-type="ref">1</xref>]. From the past efforts to cure RNA virus infections, including the experiences from the SARS and Middle East respiratory syndrome (MERS) epidemics, several potential target proteins and drugs have been proposed [<xref rid="feb213806-bib-0012" ref-type="ref">12</xref>, <xref rid="feb213806-bib-0013" ref-type="ref">13</xref>]. The 3C&#x02010;like (main) proteinase, surface glycoprotein [<xref rid="feb213806-bib-0008" ref-type="ref">8</xref>], and RNA&#x02010;dependent RNA polymerase are thought to be the most promising targets for anti&#x02010;COVID&#x02010;19 therapeutics. For example, the anti&#x02010;HIV drug lopinavir/ritonavir, which has been proposed to treat SARS [<xref rid="feb213806-bib-0014" ref-type="ref">14</xref>, <xref rid="feb213806-bib-0015" ref-type="ref">15</xref>], is expected to be effective toward SARS&#x02010;CoV&#x02010;2 3C&#x02010;like proteinase [<xref rid="feb213806-bib-0016" ref-type="ref">16</xref>, <xref rid="feb213806-bib-0017" ref-type="ref">17</xref>]. Additionally, the antiviral drug remdesivir is expected to target the RNA&#x02010;dependent RNA polymerase [<xref rid="feb213806-bib-0018" ref-type="ref">18</xref>].</p><p>The recent studies on drug repositioning/repurposing involve a variety of computational methods, such as network analysis, text mining, machine learning, and structure&#x02010;based drug repositioning (SBDR) [<xref rid="feb213806-bib-0019" ref-type="ref">19</xref>, <xref rid="feb213806-bib-0020" ref-type="ref">20</xref>, <xref rid="feb213806-bib-0021" ref-type="ref">21</xref>, <xref rid="feb213806-bib-0022" ref-type="ref">22</xref>, <xref rid="feb213806-bib-0023" ref-type="ref">23</xref>, <xref rid="feb213806-bib-0024" ref-type="ref">24</xref>]. Among these methods, SBDR is the most promising to find specific drugs toward a defined target protein, and it prompted the quick structure analyses of SARS&#x02010;CoV&#x02010;2 3C&#x02010;like proteinase and surface glycoprotein [<xref rid="feb213806-bib-0008" ref-type="ref">8</xref>, <xref rid="feb213806-bib-0025" ref-type="ref">25</xref>].</p><p>Although structure analyses of many other SARS&#x02010;CoV&#x02010;2 proteins would soon follow, predictions of other protein structures with homology/knowledge&#x02010;based (theoretical) methods would be required until structure analyses are completed, especially for the proteins currently out of focus as drug targets. In the presented study, therefore, the homology models of SARS&#x02010;CoV&#x02010;2 proteins and their ligand complexes were comprehensively constructed. Also, the structural models of the complexes between SARS&#x02010;CoV&#x02010;2 proteins and potential drugs were proposed by comparing the ligand molecules of the proteins and approved, experimental, or natural drugs.</p></sec><sec sec-type="materials-and-methods" id="feb213806-sec-0003"><title>MATERIALS AND METHODS</title><sec id="feb213806-sec-0004"><title>Homology modeling of SARS&#x02010;CoV&#x02010;2 proteins</title><p>The amino acid sequences of SARS&#x02010;CoV&#x02010;2 proteins (Table&#x000a0;<xref rid="feb213806-tbl-0001" ref-type="table">1</xref>) were retrieved from the RefSeq database at NCBI [<xref rid="feb213806-bib-0026" ref-type="ref">26</xref>], and structural modeling templates were sought with the SIRD system (<ext-link ext-link-type="uri" xlink:href="http://sird.nagahama-i-bio.ac.jp/sird/">http://sird.nagahama-i-bio.ac.jp/sird/</ext-link>), which accepted multiple query sequences and sought for similar sequences (more than 30% sequence identity to query) with known structures in the Protein Data Bank (PDB) [<xref rid="feb213806-bib-0027" ref-type="ref">27</xref>] by using BLAST [<xref rid="feb213806-bib-0028" ref-type="ref">28</xref>]. This system also sought for the templates of protein complex structures, in which two or more proteins in the multiple query were associated or any ligand bound to query proteins. The coordinates of template structures were obtained from the PDB [<xref rid="feb213806-bib-0027" ref-type="ref">27</xref>] and were rendered into the biological quaternary structures.</p><table-wrap id="feb213806-tbl-0001" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 1</label><caption><p>Models of SARS&#x02010;CoV&#x02010;2 protein<xref ref-type="fn" rid="feb213806-note-0002">
<sup>a</sup>
</xref>.</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Gene</th><th align="left" rowspan="2" valign="bottom" colspan="1">Protein</th><th align="left" rowspan="2" valign="bottom" colspan="1">Name</th><th align="left" rowspan="2" valign="bottom" colspan="1">Length</th><th align="left" colspan="5" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Model template</th><th align="left" colspan="5" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Model</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">PDB ID</th><th align="left" valign="bottom" rowspan="1" colspan="1">Identity (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Coverage (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Model description</th><th align="left" valign="bottom" rowspan="1" colspan="1">Region</th><th align="left" valign="bottom" rowspan="1" colspan="1">Interacting protein</th><th align="left" valign="bottom" rowspan="1" colspan="1">Ligand</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rotamer outlier (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Ramachandran outlier (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Clash score</th></tr></thead><tbody><tr><td align="left" rowspan="24" colspan="1">orf1ab</td><td align="left" rowspan="1" colspan="1">YP_009725297.1</td><td align="left" rowspan="1" colspan="1">Leader protein</td><td align="left" rowspan="1" colspan="1">180</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://2HSX">http://2HSX</ext-link>A</td><td align="left" rowspan="1" colspan="1">85.3</td><td align="left" rowspan="1" colspan="1">66.7</td><td align="left" rowspan="1" colspan="1">monomer(A)</td><td align="left" rowspan="1" colspan="1">A: 10&#x02013;129</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.97</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.75</td></tr><tr><td align="left" rowspan="1" colspan="1">YP_009725298.1</td><td align="left" rowspan="1" colspan="1">nsp2</td><td align="left" rowspan="1" colspan="1">638</td><td align="left" rowspan="1" colspan="1">n.a.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="6" colspan="1">YP_009725299.1</td><td align="left" rowspan="1" colspan="1">Papain&#x02010;like proteinase (nsp3)</td><td align="left" rowspan="1" colspan="1">1945</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://2IDY">http://2IDY</ext-link>A</td><td align="left" rowspan="1" colspan="1">79.3</td><td align="left" rowspan="1" colspan="1">5.9</td><td align="left" rowspan="1" colspan="1">monomer(A)</td><td align="left" rowspan="1" colspan="1">A: 1&#x02013;114</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.98</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.55</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://2FAV">http://2FAV</ext-link>C</td><td align="left" rowspan="1" colspan="1">72.5</td><td align="left" rowspan="1" colspan="1">9.2</td><td align="left" rowspan="1" colspan="1">monomer(A)</td><td align="left" rowspan="1" colspan="1">A: 202&#x02013;379</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.67</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.41</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://2WCT">http://2WCT</ext-link>B</td><td align="left" rowspan="1" colspan="1">76.3</td><td align="left" rowspan="1" colspan="1">13.9</td><td align="left" rowspan="1" colspan="1">homo&#x02010;dimer(A, B)</td><td align="left" rowspan="1" colspan="1">A, B: 410&#x02013;679</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.27</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.96</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://2KQW">http://2KQW</ext-link>A</td><td align="left" rowspan="1" colspan="1">72.7</td><td align="left" rowspan="1" colspan="1">3.7</td><td align="left" rowspan="1" colspan="1">monomer(A)</td><td align="left" rowspan="1" colspan="1">A: 675&#x02013;746</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.52</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.41</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://5E6J">http://5E6J</ext-link>A</td><td align="left" rowspan="1" colspan="1">82.0</td><td align="left" rowspan="1" colspan="1">16.6</td><td align="left" rowspan="1" colspan="1">monomer(A)</td><td align="left" rowspan="1" colspan="1">A: 745&#x02013;1067</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.35</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3.71</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://2K87">http://2K87</ext-link>A</td><td align="left" rowspan="1" colspan="1">81.0</td><td align="left" rowspan="1" colspan="1">6.3</td><td align="left" rowspan="1" colspan="1">monomer(A)</td><td align="left" rowspan="1" colspan="1">A: 1085&#x02013;1206</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.79</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3.58</td></tr><tr><td align="left" rowspan="1" colspan="1">YP_009725300.1</td><td align="left" rowspan="1" colspan="1">nsp4</td><td align="left" rowspan="1" colspan="1">500</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://3GZF">http://3GZF</ext-link>A</td><td align="left" rowspan="1" colspan="1">40.0</td><td align="left" rowspan="1" colspan="1">20.4</td><td align="left" rowspan="1" colspan="1">homo&#x02010;dimer(A, B)</td><td align="left" rowspan="1" colspan="1">A: 399&#x02013;500 B: 399&#x02013;497</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.69</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3.43</td></tr><tr><td align="left" rowspan="1" colspan="1">YP_009725301.1</td><td align="left" rowspan="1" colspan="1">3C&#x02010;like proteinase</td><td align="left" rowspan="1" colspan="1">306</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://6LU7">http://6LU7</ext-link>A</td><td align="left" rowspan="1" colspan="1">100.0</td><td align="left" rowspan="1" colspan="1">100.0</td><td align="left" rowspan="1" colspan="1">homo&#x02010;dimer(A, C)</td><td align="left" rowspan="1" colspan="1">A, C: 1&#x02013;306</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AZP, Carfilzomib</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.54</td></tr><tr><td align="left" rowspan="1" colspan="1">YP_009725302.1</td><td align="left" rowspan="1" colspan="1">nsp6</td><td align="left" rowspan="1" colspan="1">290</td><td align="left" rowspan="1" colspan="1">n.a.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">YP_009725303.1</td><td align="left" rowspan="1" colspan="1">nsp7</td><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://2KYS">http://2KYS</ext-link>A</td><td align="left" rowspan="1" colspan="1">98.8</td><td align="left" rowspan="1" colspan="1">100.0</td><td align="left" rowspan="1" colspan="1">monomer(A)</td><td align="left" rowspan="1" colspan="1">A: 1&#x02013;83</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.57</td></tr><tr><td align="left" rowspan="1" colspan="1">YP_009725304.1</td><td align="left" rowspan="1" colspan="1">nsp8</td><td align="left" rowspan="1" colspan="1">198</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://2AHM">http://2AHM</ext-link>H</td><td align="left" rowspan="1" colspan="1">97.4</td><td align="left" rowspan="1" colspan="1">98.5</td><td align="left" rowspan="1" colspan="1">hetero&#x02010;16mer(E, F, G, H, S, T, U, V)</td><td align="left" rowspan="1" colspan="1">E, S: 35&#x02013;195 F, T: 47&#x02013;195 G, U: 1&#x02013;194 H, V: 1&#x02013;195</td><td align="left" rowspan="1" colspan="1">nsp7 (A, B, C, D, O, P, Q, R)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.08</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.42</td></tr><tr><td align="left" rowspan="1" colspan="1">YP_009725305.1</td><td align="left" rowspan="1" colspan="1">nsp9</td><td align="left" rowspan="1" colspan="1">113</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://1UW7">http://1UW7</ext-link>A</td><td align="left" rowspan="1" colspan="1">97.3</td><td align="left" rowspan="1" colspan="1">100.0</td><td align="left" rowspan="1" colspan="1">homo&#x02010;dimer(A, B)</td><td align="left" rowspan="1" colspan="1">A, B: 1&#x02013;113</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.86</td></tr><tr><td align="left" rowspan="1" colspan="1">YP_009725306.1</td><td align="left" rowspan="1" colspan="1">nsp10</td><td align="left" rowspan="1" colspan="1">139</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://5NFY">http://5NFY</ext-link>H</td><td align="left" rowspan="1" colspan="1">98.5</td><td align="left" rowspan="1" colspan="1">96.4</td><td align="left" rowspan="1" colspan="1">hetero&#x02010;dimer(B)</td><td align="left" rowspan="1" colspan="1">B: 1&#x02013;134</td><td align="left" rowspan="1" colspan="1">3'&#x02010;to&#x02010;5' exonuclease (A)</td><td align="left" rowspan="1" colspan="1">ZN</td><td align="left" rowspan="1" colspan="1">1.23</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.78</td></tr><tr><td align="left" rowspan="1" colspan="1">YP_009725307.1</td><td align="left" rowspan="1" colspan="1">RNA&#x02010;dependent RNA polymerase</td><td align="left" rowspan="1" colspan="1">932</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://6NUR">http://6NUR</ext-link>A</td><td align="left" rowspan="1" colspan="1">96.3</td><td align="left" rowspan="1" colspan="1">86.8</td><td align="left" rowspan="1" colspan="1">hetero&#x02010;tetramer(A)</td><td align="left" rowspan="1" colspan="1">A: 114&#x02013;922</td><td align="left" rowspan="1" colspan="1">nsp8 (B, D), nsp7(C)</td><td align="left" rowspan="1" colspan="1">ZN</td><td align="left" rowspan="1" colspan="1">0.81</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.87</td></tr><tr><td align="left" rowspan="1" colspan="1">YP_009725308.1</td><td align="left" rowspan="1" colspan="1">Helicase</td><td align="left" rowspan="1" colspan="1">601</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://5WWP">http://5WWP</ext-link>A</td><td align="left" rowspan="1" colspan="1">71.5</td><td align="left" rowspan="1" colspan="1">99.7</td><td align="left" rowspan="1" colspan="1">monomer(A)</td><td align="left" rowspan="1" colspan="1">A: 1&#x02013;599</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ZN</td><td align="left" rowspan="1" colspan="1">1.54</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.82</td></tr><tr><td align="left" rowspan="1" colspan="1">YP_009725309.1</td><td align="left" rowspan="1" colspan="1">3'&#x02010;to&#x02010;5' Exonuclease</td><td align="left" rowspan="1" colspan="1">527</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://5NFY">http://5NFY</ext-link>D</td><td align="left" rowspan="1" colspan="1">94.7</td><td align="left" rowspan="1" colspan="1">100.0</td><td align="left" rowspan="1" colspan="1">hetero&#x02010;dimer(A)</td><td align="left" rowspan="1" colspan="1">A: 1&#x02013;527</td><td align="left" rowspan="1" colspan="1">nsp10 (B)</td><td align="left" rowspan="1" colspan="1">ZN</td><td align="left" rowspan="1" colspan="1">1.23</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.78</td></tr><tr><td align="left" rowspan="1" colspan="1">YP_009725310.1</td><td align="left" rowspan="1" colspan="1">Endo&#x02010;RNAse</td><td align="left" rowspan="1" colspan="1">346</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://2H85">http://2H85</ext-link>A</td><td align="left" rowspan="1" colspan="1">88.1</td><td align="left" rowspan="1" colspan="1">100.0</td><td align="left" rowspan="1" colspan="1">homo&#x02010;hexamer(A, B, C, D, E, F)</td><td align="left" rowspan="1" colspan="1">A, B, C, D, E, F: 1&#x02013;346</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.92</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.75</td></tr><tr><td align="left" rowspan="4" colspan="1">YP_009725311.1</td><td align="left" rowspan="1" colspan="1">2'&#x02010;<italic>O</italic>&#x02010;Ribose methyltransferase</td><td align="left" rowspan="1" colspan="1">298</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://5YNI">http://5YNI</ext-link>A</td><td align="left" rowspan="1" colspan="1">66.3</td><td align="left" rowspan="1" colspan="1">100.0</td><td align="left" rowspan="1" colspan="1">hetero&#x02010;dimer(A)</td><td align="left" rowspan="1" colspan="1">A: 1&#x02013;298</td><td align="left" rowspan="1" colspan="1">nsp10 (B)</td><td align="left" rowspan="1" colspan="1">GTG, ZN, Sinefungin</td><td align="left" rowspan="1" colspan="1">1.66</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.69</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GTG, ZN, Tecadenoson</td><td align="left" rowspan="1" colspan="1">1.66</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.55</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GTG, ZN, Selodenoson</td><td align="left" rowspan="1" colspan="1">1.39</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.55</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GTG, ZN, Trabodenoson</td><td align="left" rowspan="1" colspan="1">1.39</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.40</td></tr><tr><td align="left" rowspan="1" colspan="1">YP_009725312.1</td><td align="left" rowspan="1" colspan="1">nsp11</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">n.a.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">S</td><td align="left" rowspan="1" colspan="1">YP_009724390.1</td><td align="left" rowspan="1" colspan="1">Surface glycoprotein</td><td align="left" rowspan="1" colspan="1">1273</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://6VSB">http://6VSB</ext-link>A</td><td align="left" rowspan="1" colspan="1">100.0</td><td align="left" rowspan="1" colspan="1">88.6</td><td align="left" rowspan="1" colspan="1">homo&#x02010;trimer(A, B, C)</td><td align="left" rowspan="1" colspan="1">A, B, C: 13&#x02013;1140</td><td align="left" rowspan="1" colspan="1">ACE2 (D)</td><td align="left" rowspan="1" colspan="1">EAL</td><td align="left" rowspan="1" colspan="1">1.75</td><td align="left" rowspan="1" colspan="1">0.08</td><td align="left" rowspan="1" colspan="1">5.58</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">LPR</td><td align="left" rowspan="1" colspan="1">1.72</td><td align="left" rowspan="1" colspan="1">0.08</td><td align="left" rowspan="1" colspan="1">5.58</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">X8Z</td><td align="left" rowspan="1" colspan="1">1.72</td><td align="left" rowspan="1" colspan="1">0.08</td><td align="left" rowspan="1" colspan="1">5.60</td></tr><tr><td align="left" rowspan="1" colspan="1">ORF3a</td><td align="left" rowspan="1" colspan="1">YP_009724391.1</td><td align="left" rowspan="1" colspan="1">ORF3a protein</td><td align="left" rowspan="1" colspan="1">275</td><td align="left" rowspan="1" colspan="1">n.a.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">E</td><td align="left" rowspan="1" colspan="1">YP_009724392.1</td><td align="left" rowspan="1" colspan="1">Envelope protein</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://5X29">http://5X29</ext-link>E</td><td align="left" rowspan="1" colspan="1">91.4</td><td align="left" rowspan="1" colspan="1">90.7</td><td align="left" rowspan="1" colspan="1">homo&#x02010;pentamer(A, B, C, D, E)</td><td align="left" rowspan="1" colspan="1">A, C, D, E: 5&#x02013;68 B: 1&#x02013;68</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.67</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.63</td></tr><tr><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">YP_009724393.1</td><td align="left" rowspan="1" colspan="1">Membrane glycoprotein</td><td align="left" rowspan="1" colspan="1">222</td><td align="left" rowspan="1" colspan="1">n.a.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ORF6</td><td align="left" rowspan="1" colspan="1">YP_009724394.1</td><td align="left" rowspan="1" colspan="1">ORF6 protein</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">n.a.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ORF7a</td><td align="left" rowspan="1" colspan="1">YP_009724395.1</td><td align="left" rowspan="1" colspan="1">ORF7a protein</td><td align="left" rowspan="1" colspan="1">121</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://1YO4">http://1YO4</ext-link>A</td><td align="left" rowspan="1" colspan="1">88.4</td><td align="left" rowspan="1" colspan="1">75.2</td><td align="left" rowspan="1" colspan="1">monomer(A)</td><td align="left" rowspan="1" colspan="1">A: 11&#x02013;101</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.92</td></tr><tr><td align="left" rowspan="1" colspan="1">ORF7b</td><td align="left" rowspan="1" colspan="1">YP_009725296.1</td><td align="left" rowspan="1" colspan="1">ORF7b</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">n.a.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ORF8</td><td align="left" rowspan="1" colspan="1">YP_009724396.1</td><td align="left" rowspan="1" colspan="1">ORF8 protein</td><td align="left" rowspan="1" colspan="1">121</td><td align="left" rowspan="1" colspan="1">n.a.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">YP_009724397.2</td><td align="left" rowspan="1" colspan="1">Nucleocapsid phosphoprotein</td><td align="left" rowspan="1" colspan="1">419</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://1SSK">http://1SSK</ext-link>A</td><td align="left" rowspan="1" colspan="1">81.6</td><td align="left" rowspan="1" colspan="1">39.1</td><td align="left" rowspan="1" colspan="1">monomer(A)</td><td align="left" rowspan="1" colspan="1">A: 20&#x02013;183</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.56</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.88</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://2JW8">http://2JW8</ext-link>B</td><td align="left" rowspan="1" colspan="1">95.8</td><td align="left" rowspan="1" colspan="1">30.1</td><td align="left" rowspan="1" colspan="1">homo&#x02010;dimer(A, B)</td><td align="left" rowspan="1" colspan="1">A: 243&#x02013;367 B: 242&#x02013;367</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.48</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3.31</td></tr><tr><td align="left" rowspan="1" colspan="1">ORF10</td><td align="left" rowspan="1" colspan="1">YP_009725255.1</td><td align="left" rowspan="1" colspan="1">ORF10 protein</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">n.a.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="feb213806-ntgp-0002"><fn id="feb213806-note-0002"><label><sup>a</sup></label><p>&#x02018;Protein&#x02019; indicates RefSeq IDs of SARS&#x02010;CoV&#x02010;2 proteins and also serves as the model identifiers. &#x02018;Model template&#x02019;: &#x02018;Identity&#x02019; and &#x02018;Coverage&#x02019; show amino acid sequence identity and coverage of the template structure (&#x02018;PDB ID&#x02019;) to the corresponding SARS&#x02010;CoV&#x02010;2 proteins. &#x02018;Model&#x02019;: &#x02018;Model description&#x02019; and &#x02018;Interacting protein&#x02019; show chain ID(s) of the corresponding and bounding proteins, respectively. &#x02018;Region&#x02019; shows chain ID(s) and the start and end residue numbers of modeled region. &#x02018;Ligand&#x02019; shows the names or PDB codes of ligands in the template or model structures. &#x02018;Rotamer outlier&#x02019;, &#x02018;Ramachandran outlier&#x02019;, and &#x02018;Clash score&#x02019; show the parameters of the models.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><p>Initial structural models were constructed by using <sc>modeller</sc> [<xref rid="feb213806-bib-0029" ref-type="ref">29</xref>]. In some cases, the resultant models contain residues with rare dihedral angles (Ramachandran outliers), rare shape of side chains (rotamer outliers), and short atom&#x02013;atom distances (atomic crashes). Then, the models were further modified by iteratively applying molecular dynamics and geometry minimization procedures of <sc>phenix</sc> [<xref rid="feb213806-bib-0030" ref-type="ref">30</xref>] to eliminate aforementioned outliers, and finally, manual model modifications with visual inspection on COOT for resolving rotamer outliers or atomic crashes [<xref rid="feb213806-bib-0031" ref-type="ref">31</xref>]. The model quality was evaluated with <sc>molprobity</sc> [<xref rid="feb213806-bib-0032" ref-type="ref">32</xref>]. The percentages of rotamer outlier, Ramachandran outlier, and crash score were monitored for each model to achieve less than 2%, 0.05%, and 5, respectively.</p></sec><sec id="feb213806-sec-0005"><title>Modeling of SARS&#x02010;CoV&#x02010;2 protein complexes with potential drugs</title><p>The molecular formula of 8,085 drugs in total was retrieved from the KEGG database [<xref rid="feb213806-bib-0033" ref-type="ref">33</xref>] and the DrugBank database [<xref rid="feb213806-bib-0034" ref-type="ref">34</xref>]. The molecular formula of 5,780 metabolites in total, which have been used for natural medicines (natural drugs), was obtained from the KNApSAcK database [<xref rid="feb213806-bib-0035" ref-type="ref">35</xref>].</p><p>The structures of the ligand molecules in the known complex structures, as sought in the template search process, were exhaustively compared with that of the drugs by using COMPLIG [<xref rid="feb213806-bib-0036" ref-type="ref">36</xref>]. COMPLIG matches molecular graphs and evaluates the similarity score of two molecules A and B as min{M(A, B)/M(A), M(A, B)/M(B)}, where M(A) and M(B) are the total numbers of atoms and bonds in molecules A and B, respectively, and M(A, B) is the total number of atoms and bonds matched between molecules A and B. Both element and chirality, if applicable, should be identical for atoms, and bond order should be identical for bonds to be matched.</p><p>Selected drug molecules were built into the protein models by superposing drug molecules to known (original) ligand molecules with COMPLIG. According to the graph matching results, the dihedral angles in the drug molecules were adjusted toward the corresponding angles in the original ligand molecules, and corresponding atoms were superposed between drug and known ligand by fixing the coordinates of the latter. The models of protein&#x02013;drug complexes were further modified with PHENIX and COOT. The constraints for drug molecules were generated by using the eLBOW application in PHENIX. Hydrogen bonds were evaluated with canonical parameters (constraints were relaxed by 0.4 &#x000c5; and 20 degrees) [<xref rid="feb213806-bib-0037" ref-type="ref">37</xref>] by using CHIMERA [<xref rid="feb213806-bib-0038" ref-type="ref">38</xref>]. The protein&#x02013;ligand complexes were also assessed by using the DSX score function [<xref rid="feb213806-bib-0039" ref-type="ref">39</xref>].</p></sec></sec><sec sec-type="results" id="feb213806-sec-0006"><title>RESULTS</title><sec id="feb213806-sec-0007"><title>Models of SARS&#x02010;CoV&#x02010;2 protein</title><p>The SARS&#x02010;CoV&#x02010;2 genome encodes 11 genes (open reading frames), and the polyprotein from orf1ab is processed into 16 proteins (polypeptides) through cleavages by the papain&#x02010;like proteinase and 3C&#x02010;like proteinase activities [<xref rid="feb213806-bib-0001" ref-type="ref">1</xref>, <xref rid="feb213806-bib-0012" ref-type="ref">12</xref>, <xref rid="feb213806-bib-0040" ref-type="ref">40</xref>]. As a result of template search, the appropriate structural templates were found for 17 SARS&#x02010;CoV&#x02010;2 proteins among a total of 26, and their homology models were constructed (Table&#x000a0;<xref rid="feb213806-tbl-0001" ref-type="table">1</xref>). The 9 unmodeled proteins included those from very short ORFs, namely Nsp11 (13 amino acid residues), ORF7b (43 residues), and ORF10 (38 residues) and probable membrane proteins (nsp6, ORF3a, ORF6, M, and ORF8), which were annotated by the SOSUI server [<xref rid="feb213806-bib-0041" ref-type="ref">41</xref>].</p><p>Since a considerable amount of structural studies have already been done for SARS&#x02010;CoV and MERS&#x02010;CoV proteins, most of the available templates were from these viruses, and they had high&#x02010;sequence similarity (more than 90%) to SARS&#x02010;CoV&#x02010;2 proteins. Two proteins, namely papain&#x02010;like proteinase (nsp3) and nucleocapsid phosphoprotein, could not be modeled into a single structural model. As a result of homology search, template structures covering the entire protein were unavailable. Template structures were separated into 6 and 2 fragment/domain models, respectively. Consequently, the coverages of structural model were 56% and 69% of total residues for papain&#x02010;like proteinase (nsp3) and nucleocapsid phosphoprotein, respectively (Table&#x000a0;<xref rid="feb213806-tbl-0001" ref-type="table">1</xref>).</p><p>The third region of papain&#x02010;like proteinase (nsp3), nsp4, 3C&#x02010;like proteinase, nsp9, endo&#x02010;RNAse, surface glycoprotein, envelope protein, and C&#x02010;terminal region of nucleocapsid phosphoprotein was modeled into homo&#x02010;multimer. As the hetero&#x02010;multimeric models, nsp7 and nsp8 were modeled into hetero&#x02010;16mer; RNA&#x02010;dependent RNA polymerase, nsp7, and nsp8 were modeled as hetero&#x02010;tetramer (1:1:2 stoichiometry); 3'&#x02010;to&#x02010;5' exonuclease and nsp10 formed hetero&#x02010;dimer; 2'&#x02010;<italic>O</italic>&#x02010;ribose methyltransferase and nsp10 also formed hetero&#x02010;dimer; and homo&#x02010;trimer of surface glycoprotein was modeled in complex with human angiotensin I&#x02010;converting enzyme 2 (ACE2) (Table&#x000a0;<xref rid="feb213806-tbl-0001" ref-type="table">1</xref>).</p></sec><sec id="feb213806-sec-0008"><title>Models of SARS&#x02010;CoV&#x02010;2 protein with drug</title><p>Although the models of SARS&#x02010;CoV&#x02010;2 protein would be useful for structure&#x02010;based virtual screening, potential drugs for these proteins were sought by rather simple knowledge&#x02010;based method in the presented study. The ligand molecules that were complexed with the homologs of SARS&#x02010;CoV&#x02010;2 protein in the PDB were extracted, and structurally similar molecules to the ligands were sought among the approved/experimental drugs retrieved from the KEGG database [<xref rid="feb213806-bib-0033" ref-type="ref">33</xref>] and the DrugBank database [<xref rid="feb213806-bib-0034" ref-type="ref">34</xref>]. Many of the approved drugs, such as morphine, aspirin, or penicillin, have been adapted from natural medicines [<xref rid="feb213806-bib-0042" ref-type="ref">42</xref>, <xref rid="feb213806-bib-0043" ref-type="ref">43</xref>]. The molecules in the natural medicines are expected to serve as argent therapeutics. Therefore, the ligand structures were also compared with the components of natural medicines (natural drugs) registered in the KNApSAcK database [<xref rid="feb213806-bib-0035" ref-type="ref">35</xref>].</p><p>The original ligand molecules and the detected drug molecules are summarized in Table&#x000a0;<xref rid="feb213806-tbl-0002" ref-type="table">2</xref>. A total of 11 ligand molecules were matched to 21 approved/experimental and 5 natural drugs, and the complex models of the SARS&#x02010;CoV&#x02010;2 proteins with several promising drugs, those with high similarity score or placed in higher ranking, were constructed as follows.</p><table-wrap id="feb213806-tbl-0002" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 2</label><caption><p>Potential drugs for SARS&#x02010;CoV&#x02010;2<xref ref-type="fn" rid="feb213806-note-0003">
<sup>a</sup>
</xref>.</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Ligand name</th><th align="left" valign="top" rowspan="1" colspan="1">Ligand code</th><th align="left" valign="top" rowspan="1" colspan="1">Protein name</th><th align="left" valign="top" rowspan="1" colspan="1">Protein sources</th><th align="left" valign="top" rowspan="1" colspan="1">PDB IDs</th><th align="left" valign="top" rowspan="1" colspan="1">Score</th><th align="left" valign="top" rowspan="1" colspan="1">Drug name</th><th align="left" valign="top" rowspan="1" colspan="1">DB codes</th></tr></thead><tbody><tr><td align="left" rowspan="5" colspan="1">
<italic>S</italic>&#x02010;adenosyl&#x02010;<sc>l</sc>&#x02010;methionine</td><td align="left" rowspan="5" colspan="1">SAM</td><td align="left" rowspan="5" colspan="1">2'&#x02010;<italic>O</italic>&#x02010;Ribose methyltransferase (nsp16)</td><td align="left" rowspan="5" colspan="1">SARS&#x02010;CoV, human betacoronavirus 2C EMC/2012</td><td align="left" rowspan="5" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://5C8T">http://5C8T</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://3R24">http://3R24</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://5YNI">http://5YNI</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://5YNM">http://5YNM</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://5YN6">http://5YN6</ext-link>
</td><td align="left" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">Ademetionine</td><td align="left" rowspan="1" colspan="1">D07128</td></tr><tr><td align="left" rowspan="1" colspan="1">0.946</td><td align="left" rowspan="1" colspan="1">Sinefungin</td><td align="left" rowspan="1" colspan="1">C00052045, D05846</td></tr><tr><td align="left" rowspan="1" colspan="1">0.862</td><td align="left" rowspan="1" colspan="1">Tecadenoson</td><td align="left" rowspan="1" colspan="1">D06019</td></tr><tr><td align="left" rowspan="1" colspan="1">0.814</td><td align="left" rowspan="1" colspan="1">Selodenoson</td><td align="left" rowspan="1" colspan="1">D05818</td></tr><tr><td align="left" rowspan="1" colspan="1">0.814</td><td align="left" rowspan="1" colspan="1">Trabodenoson</td><td align="left" rowspan="1" colspan="1">D10493</td></tr><tr><td align="left" rowspan="5" colspan="1">Sinefungin</td><td align="left" rowspan="5" colspan="1">SFG</td><td align="left" rowspan="5" colspan="1">2'&#x02010;<italic>O</italic>&#x02010;Ribose methyltransferase (nsp16)</td><td align="left" rowspan="5" colspan="1">SARS&#x02010;CoV, human betacoronavirus 2C EMC/2012</td><td align="left" rowspan="5" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://2XYR">http://2XYR</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://5YNN">http://5YNN</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://5YNP">http://5YNP</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://5YNB">http://5YNB</ext-link>
</td><td align="left" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">Sinefungin</td><td align="left" rowspan="1" colspan="1">C00052045, D05846</td></tr><tr><td align="left" rowspan="1" colspan="1">0.946</td><td align="left" rowspan="1" colspan="1">Ademetionine</td><td align="left" rowspan="1" colspan="1">D07128</td></tr><tr><td align="left" rowspan="1" colspan="1">0.862</td><td align="left" rowspan="1" colspan="1">Tecadenoson</td><td align="left" rowspan="1" colspan="1">D06019</td></tr><tr><td align="left" rowspan="1" colspan="1">0.832</td><td align="left" rowspan="1" colspan="1">Adenosine monophosphate</td><td align="left" rowspan="1" colspan="1">D02769</td></tr><tr><td align="left" rowspan="1" colspan="1">0.832</td><td align="left" rowspan="1" colspan="1">Selodenoson</td><td align="left" rowspan="1" colspan="1">D05818</td></tr><tr><td align="left" rowspan="2" colspan="1">7&#x02010;Methyl&#x02010;Guanosine&#x02010;5'&#x02010;Triphosphate&#x02010;5'&#x02010;Guanosine</td><td align="left" rowspan="2" colspan="1">GTG</td><td align="left" rowspan="2" colspan="1">2'&#x02010;<italic>O</italic>&#x02010;Ribose methyltransferase</td><td align="left" rowspan="2" colspan="1">Human betacoronavirus 2C EMC/2012</td><td align="left" rowspan="2" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://5YNI">http://5YNI</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://5YNN">http://5YNN</ext-link>
</td><td align="left" rowspan="1" colspan="1">0.788</td><td align="left" rowspan="1" colspan="1">Nadide</td><td align="left" rowspan="1" colspan="1">D00002</td></tr><tr><td align="left" rowspan="1" colspan="1">0.763</td><td align="left" rowspan="1" colspan="1">Diquafosol tetrasodium</td><td align="left" rowspan="1" colspan="1">D03864</td></tr><tr><td align="left" rowspan="1" colspan="1">Ace&#x02010;Ser&#x02010;Ala&#x02010;Val&#x02010;ALC&#x02010;His&#x02010;H</td><td align="left" rowspan="1" colspan="1">n.a</td><td align="left" rowspan="1" colspan="1">3C&#x02010;like proteinase</td><td align="left" rowspan="1" colspan="1">SARS&#x02010;CoV</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://3AVZ">http://3AVZ</ext-link>
</td><td align="left" rowspan="1" colspan="1">n.d.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">N&#x02010;[(5&#x02010;methylisoxazol&#x02010;3&#x02010;yl)carbonyl]alanyl&#x02010;L&#x02010;valyl&#x02010;N&#x000a0;~&#x000a0;1&#x02010;((1R,2Z)&#x02010;4&#x02010;(benzyloxy)&#x02010;4&#x02010;oxo&#x02010;1&#x02010;{[(3R)&#x02010;2&#x02010;oxopyrrolidin&#x02010;3&#x02010;yl]methyl}but&#x02010;2&#x02010;enyl)&#x02010;L&#x02010;leucinamide</td><td align="left" rowspan="1" colspan="1">n.a</td><td align="left" rowspan="1" colspan="1">3C&#x02010;like proteinase</td><td align="left" rowspan="1" colspan="1">SARS&#x02010;CoV&#x02010;2</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://6LU7">http://6LU7</ext-link>
</td><td align="left" rowspan="1" colspan="1">n.d.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">C4Z inhibitor</td><td align="left" rowspan="1" colspan="1">n.a</td><td align="left" rowspan="1" colspan="1">3C&#x02010;like proteinase</td><td align="left" rowspan="1" colspan="1">SARS&#x02010;CoV</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://3VB5">http://3VB5</ext-link>
</td><td align="left" rowspan="1" colspan="1">n.d.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="4" colspan="1">Ac&#x02010;ESTLQ&#x02010;H</td><td align="left" rowspan="4" colspan="1">n.a</td><td align="left" rowspan="4" colspan="1">3C&#x02010;like proteinase</td><td align="left" rowspan="4" colspan="1">SARS&#x02010;CoV</td><td align="left" rowspan="4" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://3SND">http://3SND</ext-link>
</td><td align="left" rowspan="1" colspan="1">0.783</td><td align="left" rowspan="1" colspan="1">Magnesium pidolate</td><td align="left" rowspan="1" colspan="1">D08263</td></tr><tr><td align="left" rowspan="1" colspan="1">0.779</td><td align="left" rowspan="1" colspan="1">Decanal</td><td align="left" rowspan="1" colspan="1">C00030099</td></tr><tr><td align="left" rowspan="1" colspan="1">0.779</td><td align="left" rowspan="1" colspan="1">1&#x02010;Decanol</td><td align="left" rowspan="1" colspan="1">C00030100</td></tr><tr><td align="left" rowspan="1" colspan="1">0.775</td><td align="left" rowspan="1" colspan="1">Undecanal</td><td align="left" rowspan="1" colspan="1">C00032442</td></tr><tr><td align="left" rowspan="1" colspan="1">(5s,8s,14r)&#x02010;Ethyl 11&#x02010;(3&#x02010;Amino&#x02010;3&#x02010; Oxopropyl)&#x02010;8&#x02010;Benzyl&#x02010;14&#x02010;Hydroxy&#x02010;5&#x02010;Isobutyl&#x02010;3,6,9,12&#x02010;Tetraoxo&#x02010;1&#x02010;Phenyl&#x02010;2&#x02010;Oxa&#x02010;4,7,10,11&#x02010;Tetraazapentadecan&#x02010;15&#x02010;Oate</td><td align="left" rowspan="1" colspan="1">AZP</td><td align="left" rowspan="1" colspan="1">3C&#x02010;like proteinase</td><td align="left" rowspan="1" colspan="1">SARS&#x02010;CoV</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://2GTB">http://2GTB</ext-link>
</td><td align="left" rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">Carfilzomib</td><td align="left" rowspan="1" colspan="1">D08880</td></tr><tr><td align="left" rowspan="5" colspan="1">1&#x02010;((2S)&#x02010;2&#x02010;{[(1S)&#x02010;1&#x02010;Carboxy&#x02010;3&#x02010;Phenylpropyl]Amino}Propanpyl)&#x02010;L&#x02010;Proline</td><td align="left" rowspan="5" colspan="1">EAL</td><td align="left" rowspan="5" colspan="1">ACE</td><td align="left" rowspan="5" colspan="1">Human</td><td align="left" rowspan="5" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://1UZE">http://1UZE</ext-link>
</td><td align="left" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">Enalaprilat</td><td align="left" rowspan="1" colspan="1">D03769</td></tr><tr><td align="left" rowspan="1" colspan="1">0.932</td><td align="left" rowspan="1" colspan="1">Lisinopril</td><td align="left" rowspan="1" colspan="1">D00362</td></tr><tr><td align="left" rowspan="1" colspan="1">0.926</td><td align="left" rowspan="1" colspan="1">Enalaprilat</td><td align="left" rowspan="1" colspan="1">D00621</td></tr><tr><td align="left" rowspan="1" colspan="1">0.925</td><td align="left" rowspan="1" colspan="1">Spiraprilat</td><td align="left" rowspan="1" colspan="1">D03775</td></tr><tr><td align="left" rowspan="1" colspan="1">0.918</td><td align="left" rowspan="1" colspan="1">Lisinopril</td><td align="left" rowspan="1" colspan="1">D00362</td></tr><tr><td align="left" rowspan="5" colspan="1">[<italic>N</italic>2&#x02010;[(<italic>S</italic>)&#x02010;1&#x02010;Carboxy&#x02010;3&#x02010;phenylpropyl]&#x02010;L&#x02010;lysyl&#x02010;L&#x02010;proline</td><td align="left" rowspan="5" colspan="1">LPR</td><td align="left" rowspan="5" colspan="1">ACE somatic isoform</td><td align="left" rowspan="5" colspan="1">Human</td><td align="left" rowspan="5" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://1O86">http://1O86</ext-link>
</td><td align="left" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">Lisinopril</td><td align="left" rowspan="1" colspan="1">D00362</td></tr><tr><td align="left" rowspan="1" colspan="1">0.932</td><td align="left" rowspan="1" colspan="1">Enalaprilat</td><td align="left" rowspan="1" colspan="1">D03769</td></tr><tr><td align="left" rowspan="1" colspan="1">0.896</td><td align="left" rowspan="1" colspan="1">Enalaprilat</td><td align="left" rowspan="1" colspan="1">D07892</td></tr><tr><td align="left" rowspan="1" colspan="1">0.867</td><td align="left" rowspan="1" colspan="1">Ceronapril</td><td align="left" rowspan="1" colspan="1">D03440</td></tr><tr><td align="left" rowspan="1" colspan="1">0.857</td><td align="left" rowspan="1" colspan="1">Spiraprilat</td><td align="left" rowspan="1" colspan="1">D03775</td></tr><tr><td align="left" rowspan="5" colspan="1">L&#x02010;Captopril</td><td align="left" rowspan="5" colspan="1">X8Z</td><td align="left" rowspan="5" colspan="1">ACE</td><td align="left" rowspan="5" colspan="1">Human</td><td align="left" rowspan="5" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://4C2P">http://4C2P</ext-link>
</td><td align="left" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">Captopril</td><td align="left" rowspan="1" colspan="1">D00251</td></tr><tr><td align="left" rowspan="1" colspan="1">0.853</td><td align="left" rowspan="1" colspan="1">Telmesteine</td><td align="left" rowspan="1" colspan="1">D08565</td></tr><tr><td align="left" rowspan="1" colspan="1">0.851</td><td align="left" rowspan="1" colspan="1">Oxaceprol</td><td align="left" rowspan="1" colspan="1">D07215</td></tr><tr><td align="left" rowspan="1" colspan="1">0.795</td><td align="left" rowspan="1" colspan="1">Undecanoic acid</td><td align="left" rowspan="1" colspan="1">C00007421</td></tr><tr><td align="left" rowspan="1" colspan="1">0.795</td><td align="left" rowspan="1" colspan="1">Bucillamine</td><td align="left" rowspan="1" colspan="1">D01809</td></tr></tbody></table><table-wrap-foot id="feb213806-ntgp-0003"><fn id="feb213806-note-0003"><label><sup>a</sup></label><p>&#x02018;Protein source&#x02019; and &#x02018;PDB ID&#x02019; are the source organisms and PDB of the template structures, respectively. &#x02018;Ligand code&#x02019; is HETATM code in PDB. &#x02018;DB code&#x02019; is headed by D and C for the IDs of the molecules in KEGG and KNApSAcK, respectively. &#x02018;Score&#x02019; indicates the similarity score of each drug molecule in KEGG or KNApSAcK to the ligand in the template structures computed by COMPLIG (see <xref rid="feb213806-sec-0002" ref-type="sec">Materials and methods</xref>).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap></sec><sec id="feb213806-sec-0009"><title>3C&#x02010;like proteinase</title><p>3C&#x02010;like proteinase is involved in the processing of viral polyprotein [<xref rid="feb213806-bib-0044" ref-type="ref">44</xref>]. This enzyme is one of the most extensively studied drug targets and thus analyzed in complex with various peptide mimetic inhibitors [<xref rid="feb213806-bib-0045" ref-type="ref">45</xref>, <xref rid="feb213806-bib-0046" ref-type="ref">46</xref>, <xref rid="feb213806-bib-0047" ref-type="ref">47</xref>, <xref rid="feb213806-bib-0048" ref-type="ref">48</xref>]. Unexpectedly, these ligands did not show very high similarity to known drug molecules (Table&#x000a0;<xref rid="feb213806-tbl-0002" ref-type="table">2</xref>). As a peptide mimetic drug, carfilzomib showed highest score to the template ligand (ligand code AZP) of 3C&#x02010;like proteinase homolog (Fig.&#x000a0;<xref rid="feb213806-fig-0001" ref-type="fig">1A</xref>). However, the similarity score between the ligand and the drug was only 0.754. Carfilzomib is the irreversible proteasome inhibitor targeted to the subunits with chymotrypsin&#x02010;like activity and has been approved for refractory multiple myeloma or Waldenstr&#x000f6;m's macroglobulinemia [<xref rid="feb213806-bib-0049" ref-type="ref">49</xref>, <xref rid="feb213806-bib-0050" ref-type="ref">50</xref>]. A complex model of carfilzomib&#x02013;SARS&#x02010;CoV&#x02010;2 3C&#x02010;like proteinase was constructed. In the model, carfilzomib formed a parallel &#x003b2;&#x02010;sheet with His164&#x02013;Glu166, and side chains of His41, Cys145, Met165, Leu167, Phe185, and Gln189 contributed major interactions (Fig.&#x000a0;<xref rid="feb213806-fig-0001" ref-type="fig">1B,C</xref>). These residues were conserved between the template (SARS&#x02010;CoV) and the model (SARS&#x02010;CoV&#x02010;2) proteins. Carfilzomib covalently binds to active site threonine through epoxy moiety, and the epoxy moiety is also reactive with thiol group of cysteine. Although a possible covalent linkage between carfilzomib and the catalytic Cys145 of SARS&#x02010;CoV&#x02010;2 3C&#x02010;like proteinase was not explicitly modeled, the epoxy moiety was placed close to the catalytic residue in this model. The fitness of the ligand to SARS&#x02010;CoV&#x02010;2 3C&#x02010;like proteinase in the model was evaluated by the DSX function, and the score of carfilzomib, &#x02013;139.6, was even better than that (&#x02212;99.8) of inhibitor N3 in the complex crystal structure of SARS&#x02010;CoV&#x02010;2 3C&#x02010;like proteinase (PDB ID <ext-link ext-link-type="uri" xlink:href="http://6LU7">http://6LU7</ext-link>).</p><fig fig-type="Fig." xml:lang="en" id="feb213806-fig-0001" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>3C&#x02010;like proteinase&#x02013;carfilzomib model. (A) Formula of (5s, 8s, 14r)&#x02010;ethyl 11&#x02010;(3&#x02010;amino&#x02010;3&#x02010;oxopropyl)&#x02010;8&#x02010;benzyl&#x02010;14&#x02010;hydroxy&#x02010;5&#x02010;isobutyl&#x02010;3, 6, 9, 12&#x02010;tetraoxo&#x02010;1&#x02010;phenyl&#x02010;2&#x02010;oxa&#x02010;4, 7, 10, 11&#x02010;tetraazapentadecan&#x02010;15&#x02010;oate (template ligand with ligand code AZP), carfilzomib, and lopinavir/ritonavir. (B) Overall structure of the model. (C) Close view of the carfilzomib binding site. Hydrogen bonds are shown in yellow lines.</p></caption><graphic id="nlm-graphic-3" xlink:href="FEB2-9999-na-g001"/></fig></sec><sec id="feb213806-sec-0010"><title>Surface glycoprotein&#x02013;ACE2 complex</title><p>Surface glycoprotein is used for a viral entrance into the host cell, and its cell surface receptor is human angiotensin I&#x02010;converting enzyme 2 (ACE2) [<xref rid="feb213806-bib-0051" ref-type="ref">51</xref>]. ACE, a homolog of ACE2 sharing 44% amino acid sequence identity, is a major target of hypertension medicating drugs, and several ACE&#x02013;drug complexes have been reported [<xref rid="feb213806-bib-0052" ref-type="ref">52</xref>, <xref rid="feb213806-bib-0053" ref-type="ref">53</xref>, <xref rid="feb213806-bib-0054" ref-type="ref">54</xref>]. Lisinopril, enalaprilat, and captopril, which show similar structures to each other (Fig.&#x000a0;<xref rid="feb213806-fig-0002" ref-type="fig">2A</xref>), have been targeted toward ACE and approved for hypertension treatments [<xref rid="feb213806-bib-0055" ref-type="ref">55</xref>, <xref rid="feb213806-bib-0056" ref-type="ref">56</xref>, <xref rid="feb213806-bib-0057" ref-type="ref">57</xref>, <xref rid="feb213806-bib-0058" ref-type="ref">58</xref>]. In the structural complex models, these drugs were bound to the protein through a Zn<sup>2+</sup> coordination with Glu384, His356, and His360 (Fig.&#x000a0;<xref rid="feb213806-fig-0002" ref-type="fig">2B,C</xref>). These residues were conserved between the template (ACE) and the model (ACE2) structures. The drug molecules also formed electrostatic interactions with Arg255 and Arg500 even though these residues were not conserved between ACE and ACE2 (Gln259 and Ser504 in ACE). The SARS&#x02010;CoV&#x02010;2 surface glycoprotein interacted with ACE2 through the receptor&#x02010;binding domain (RBD), while the bound drugs had no direct interaction to the RBD (Fig.&#x000a0;<xref rid="feb213806-fig-0002" ref-type="fig">2C</xref>), suggesting that those drugs would not directly interfere the host&#x02013;pathogen interaction.</p><fig fig-type="Fig." xml:lang="en" id="feb213806-fig-0002" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Surface glycoprotein&#x02013;ACE2&#x02013;lisinopril/enalaprilat/captopril model. (A) Formula of lisinopril (ligand code LPR), enalaprilat (EAL), and captopril (X8Z). (B) Overall structure of the model. (C) Close view of the lisinopril/enalaprilat/captopril binding site. Hydrogen bonds are shown in yellow lines. Lisinopril, enalaprilat, and captopril were superposed, and the carbon atoms were colored light blue, gray, and magenta, respectively.</p></caption><graphic id="nlm-graphic-5" xlink:href="FEB2-9999-na-g002"/></fig><p>The DSX scores for lisinopril, enalaprilat, and captopril in the models were &#x02212;32.7, &#x02212;43.6, and &#x02212;25.0, respectively. These scores were considerably inferior to that (&#x02212;74.6) of the specific inhibitor MLN&#x02010;4760 in the crystal structure of human ACE2 complex (PDB ID <ext-link ext-link-type="uri" xlink:href="http://1R4L">http://1R4L</ext-link>) [<xref rid="feb213806-bib-0059" ref-type="ref">59</xref>].</p></sec><sec id="feb213806-sec-0011"><title>2&#x02019;&#x02010;O&#x02010;Ribose methyltransferase</title><p>The complex of 2&#x02019;&#x02010;<italic>O</italic>&#x02010;ribose methyltransferase (nsp16) and nsp10 is involved in the modification of the viral RNA caps [<xref rid="feb213806-bib-0060" ref-type="ref">60</xref>]. The structure of 2&#x02019;&#x02010;<italic>O</italic>&#x02010;ribose methyltransferase subunit was determined in complex with <italic>S</italic>&#x02010;adenosyl&#x02010;<sc>l</sc>&#x02010;methionine (ligand code SAM), 7&#x02010;methyl&#x02010;guanosine&#x02010;5'&#x02010;triphosphate&#x02010;5'&#x02010;guanosine (GTG), and sinefungin (SFG) [<xref rid="feb213806-bib-0061" ref-type="ref">61</xref>, <xref rid="feb213806-bib-0062" ref-type="ref">62</xref>, <xref rid="feb213806-bib-0063" ref-type="ref">63</xref>]. Among these ligands, <italic>S</italic>&#x02010;adenosyl&#x02010;<sc>l</sc>&#x02010;methionine is used for a therapeutic against depression, liver disorders, fibromyalgia, and osteoarthritis [<xref rid="feb213806-bib-0064" ref-type="ref">64</xref>], but also is an authentic substrate for this enzyme. Sinefungin is a natural drug produced by <italic>Streptomyces griseolus</italic> and experimentally used as antibiotics [<xref rid="feb213806-bib-0065" ref-type="ref">65</xref>, <xref rid="feb213806-bib-0066" ref-type="ref">66</xref>, <xref rid="feb213806-bib-0067" ref-type="ref">67</xref>] (Fig.&#x000a0;<xref rid="feb213806-fig-0003" ref-type="fig">3A</xref>).</p><fig fig-type="Fig." xml:lang="en" id="feb213806-fig-0003" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>2&#x02032;&#x02010;<italic>O</italic>&#x02010;Ribose methyltransferase (nsp16)&#x02013;nsp10&#x02013;sinefungin/tecadenoson/ selodenoson/trabodenoson model. (A) Formula of sinefungin (ligand code SFG), tecadenoson, selodenoson, and trabodenoson. (B) Overall structure of the model. (C) Close view of the binding site for sinefungin (SFG) and trabodenoson. Hydrogen bonds are shown in yellow lines.</p></caption><graphic id="nlm-graphic-7" xlink:href="FEB2-9999-na-g003"/></fig><p>The residues of 2&#x02019;&#x02010;<italic>O&#x02010;</italic>ribose methyltransferase, Ser74, Asp99, Asn101, Asp130, and Met131, were involved in the major interactions with sinefungin (Fig.&#x000a0;<xref rid="feb213806-fig-0003" ref-type="fig">3B,C</xref>). These residues were conserved among the template proteins (SARS&#x02010;CoV and betacoronavirus) and SARS&#x02010;CoV&#x02010;2.</p><p>As the drugs similar to these ligands, several investigational adenosine A1 receptor agonists, namely tecadenoson, selodenoson, and trabodenoson, were found (Fig.&#x000a0;<xref rid="feb213806-fig-0003" ref-type="fig">3A</xref>). These molecules share adenosine moiety, and this moiety interacts with the aforementioned 5 conserved residues in the complex models. The DSX scores of sinefungin, tecadenoson, selodenoson, and trabodenoson were &#x02212;75.6, &#x02212;54.3, &#x02212;70.0, and &#x02212;55.3, respectively. The scores of sinefungin and selodenoson were comparable to that (&#x02212;74.9) of the genuine substrate, <italic>S</italic>&#x02010;adenosyl&#x02010;<sc>l</sc>&#x02010;methionine, in the complex crystal structure with MERS&#x02010;CoV 2&#x02019;&#x02010;<italic>O</italic>&#x02010;ribose methyltransferase (PDB ID <ext-link ext-link-type="uri" xlink:href="http://5YNI">http://5YNI</ext-link>).</p></sec></sec><sec sec-type="discussion" id="feb213806-sec-0012"><title>DISCUSSION</title><p>In the presented study, knowledge&#x02010;based models of SARS&#x02010;CoV&#x02010;2 proteins were constructed by homology modeling and comparison of the known ligands with drugs. Since a considerable number of structure analyses have already reported for coronavirus proteins including those of SARS&#x02010;CoV, 66% (17/26) of the SARS&#x02010;CoV&#x02010;2 proteins could be modeled based on highly similar (85% sequence identity and 89% coverage on average) templates (Table&#x000a0;<xref rid="feb213806-tbl-0001" ref-type="table">1</xref>).</p><p>Several drugs were suggested to bind to the SARS&#x02010;CoV&#x02010;2 targets (Table&#x000a0;<xref rid="feb213806-tbl-0002" ref-type="table">2</xref>). The procedure employed in the presented study should largely limit the extent of search (because it depends on the presence of ligands in known complex structures). However, it is noteworthy that the binding of suggested drugs to the homologous proteins of the SARS&#x02010;CoV&#x02010;2 targets would be probable because of the presence of structural evidences.</p><p>The complex models were constructed for several high&#x02010;scored and/or high&#x02010;ranked drugs. Unexpectedly, no drug was detected for one of the most promising drug targets, 3C&#x02010;like proteinase, with a similarity score higher than 0.8. In the previous study, the score more than 0.8 was suggested to be required for highly similar interactions between ligand and protein [<xref rid="feb213806-bib-0036" ref-type="ref">36</xref>]. It is implied that the inhibitors bound to the 3C&#x02010;like proteinase in the known structures are considerably deviated from most of the approved protease&#x02010;targeted drugs. For example, the anti&#x02010;HIV drug lopinavir/ritonavir, which was expected to target SARS&#x02010;CoV&#x02010;2 3C&#x02010;like proteinase [<xref rid="feb213806-bib-0016" ref-type="ref">16</xref>, <xref rid="feb213806-bib-0017" ref-type="ref">17</xref>], showed only limited similarity (score 0.513) to the known ligand (ligand code AXP) of SARS&#x02010;CoV 3C&#x02010;like proteinase (Fig.&#x000a0;<xref rid="feb213806-fig-0002" ref-type="fig">2A</xref>). One possible reason for the low similarity to drugs is that the protease inhibitors tend to have higher molecular weight and thus their molecular structures showed large variety. Another reason would be that a majority of the protease inhibitory drugs are targeted toward serine or zinc proteases [<xref rid="feb213806-bib-0068" ref-type="ref">68</xref>, <xref rid="feb213806-bib-0069" ref-type="ref">69</xref>]. Also, the expected drug lopinavir/ritonavir has been designed for HIV protease, which is aspartic protease. These proteases are structurally distinct from 3C&#x02010;like proteinase known to be a cysteine protease. This observation implies that structure optimizations would likely be required for repurposed drugs for SARS&#x02010;CoV&#x02010;2 3C&#x02010;like proteinase. Consequently, the presented study suggested carfilzomib, which has been targeted toward threonine protease and approved for multiple myeloma treatment [<xref rid="feb213806-bib-0049" ref-type="ref">49</xref>, <xref rid="feb213806-bib-0050" ref-type="ref">50</xref>], as a marginally resembling drug. The model showed, however, carfilzomib fits well (even better than the specific inhibitor N3, according to the DSX score) into the active site by forming considerable stabilizing interactions and no severe steric hindrance (Fig.&#x000a0;<xref rid="feb213806-fig-0001" ref-type="fig">1C</xref>).</p><p>Another potential target is the complex of surface glycoprotein and ACE2 to prevent virus entry into the cell [<xref rid="feb213806-bib-0070" ref-type="ref">70</xref>, <xref rid="feb213806-bib-0071" ref-type="ref">71</xref>]. Many hypertension drugs are targeted to ACE, and the presented study highlighted the approved drugs, namely lisinopril, enalaprilat, and captopril, as potential ligands for ACE2. An expectation in advance was to find a drug that bound to ACE2 and also interfered the interactions between surface glycoprotein and ACE2. However, as the models revealed, the drug&#x02010;binding site of ACE2 existed inside a deep cleft in the center of ACE2 molecule, and the ligands do not interact directly with the surface glycoprotein (Fig.&#x000a0;<xref rid="feb213806-fig-0002" ref-type="fig">2C</xref>).</p><p>The human ACE2 has been demonstrated to change its conformation from open to close forms (PDB IDs <ext-link ext-link-type="uri" xlink:href="http://1R4L">http://1R4L</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://1R42">http://1R42</ext-link>, respectively) upon inhibitor binding [<xref rid="feb213806-bib-0059" ref-type="ref">59</xref>]. Thus, if this conformational change involves the interface to the RBD of surface glycoprotein, a drug bound to the drug&#x02010;binding site might interfere with the binding between ACE2 and surface glycoprotein indirectly. This allosteric inhibition mechanism, however, is not highly expected because no obvious conformational change was observed in the interface region when comparing the open and close conformations of ACE2. Most of the predicted drugs are targeted toward ACE (not ACE2), and ACE and ACE2 diverge considerably in their amino acid sequences (44% identity). The fitness of the drugs was evaluated to be lower than the specific inhibitor to ACE2. Therefore, effects of the predicted ACE drugs on preventing surface glycoprotein&#x02013;ACE2 interactions would not be highly promising.</p><p>Another target presented results highlighted was 2&#x02019;&#x02010;<italic>O</italic>&#x02010;ribose methyltransferase (nsp16)&#x02013;nsp10 complex, which is less focused as a target of drug repurposing. 2&#x02019;&#x02010;<italic>O</italic>&#x02010;ribose methyltransferase is required to finalize the cap structure, <sup>7Me</sup>GpppA<sub>2'OMe</sub>, of coronavirus RNAs by transferring a methyl group to 2&#x02019; OH group of ribonucleotide from <italic>S</italic>&#x02010;adenosyl&#x02010;<sc>l</sc>&#x02010;methionine [<xref rid="feb213806-bib-0072" ref-type="ref">72</xref>, <xref rid="feb213806-bib-0073" ref-type="ref">73</xref>]. The cap structure is essential for viral mRNAs to be translated and escape from innate immune system in the host cell. Thus, inhibition of this enzyme might prevent virus propagation. Despite the overall sequence identities between templates (SARS&#x02010;CoV or human betacoronavirus) and SARS&#x02010;CoV&#x02010;2 enzymes were relatively low (~66%), the residues interacting with the drugs were conserved.</p><p>Among the suggested drugs for this enzyme, sinefungin is a naturally occurring and verified inhibitor of 2&#x02019;&#x02010;<italic>O</italic>&#x02010;ribose methyltransferase. Since a toxicity was detected [<xref rid="feb213806-bib-0074" ref-type="ref">74</xref>], however, appreciation of this natural drug should be carefully considered. Although tecadenoson has been examined in a clinical trial for atrial fibrillation, and passed phase II test, final results were not formally reported at this point of time [<xref rid="feb213806-bib-0075" ref-type="ref">75</xref>]. Trabodenoson was designed for treating ocular hypertension and primary open&#x02010;angle glaucoma [<xref rid="feb213806-bib-0076" ref-type="ref">76</xref>], but had failed in the phase III clinical trial test due to lack of superiority over placebo. Selodenoson was designed to control heart rate [<xref rid="feb213806-bib-0077" ref-type="ref">77</xref>], and it seems still in a developmental stage. Since tecadenoson and trabodenoson appeared to have cleared the phase I tests, these drugs would worth examining against COVID&#x02010;19. The DSX score suggested the fitness of sinefungin or selodenoson is comparable to the genuine substrate of the 2&#x02019;&#x02010;<italic>O</italic>&#x02010;ribose methyltransferase.</p><p>Several structure determinations of SARS&#x02010;CoV&#x02010;2 proteins, for example, endo&#x02010;RNase (PDB IDs <ext-link ext-link-type="uri" xlink:href="http://6VWW">http://6VWW</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://6VW01">http://6VW01</ext-link>), nucleocapsid phosphoprotein (<ext-link ext-link-type="uri" xlink:href="http://6VYO">http://6VYO</ext-link>), and nsp12 (RNA&#x02010;dependent RNA polymerase)&#x02010;nsp7&#x02010;nsp8 complex (PDB ID <ext-link ext-link-type="uri" xlink:href="http://7BV2">http://7BV2</ext-link>) have been reported after the modeling of the presented study was executed. Although many of the other proteins should be under analyses undoubtedly, it would take considerable time before all structures of potential targets are experimentally elucidated. During the period until the structural determinations, theoretical models might be useful. The presented structural models are freely available from the BINDS webpage (<ext-link ext-link-type="uri" xlink:href="https://www.binds.jp/SARS-CoV-2/">https://www.binds.jp/SARS-CoV-2/</ext-link>) and also deposited in the BSM&#x02010;Arc repository (BSM00015) [<xref rid="feb213806-bib-0078" ref-type="ref">78</xref>].</p></sec><sec id="feb213806-sec-0014"><title>Author contributions</title><p>MO, SK, and TS conceived and designed the study. AH, CS, SN, MS, and TS constructed the models. AH, CS, and TS wrote the manuscript. All authors commented on the manuscript.</p></sec></body><back><ack id="feb213806-sec-0013"><title>Acknowledgements</title><p>This work was partly supported by the Platform Project for Supporting Drug Discovery and Life Science Research (Basis of Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED (JP20am0101111 and JP20am0101069).</p></ack><ref-list content-type="cited-references" id="feb213806-bibl-0001"><title>References</title><ref id="feb213806-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="feb213806-cit-0001">
<string-name>
<surname>Wu</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>YM</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>ZG</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tao</surname>
<given-names>ZW</given-names>
</string-name>, <string-name>
<surname>Tian</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Pei</surname>
<given-names>YY</given-names>
</string-name>
<italic>et al</italic> (<year>2020</year>) <article-title>A new coronavirus associated with human respiratory disease in China</article-title>. <source xml:lang="en">Nature</source>, <volume>579</volume>, <fpage>265</fpage>&#x02013;<lpage>269</lpage>.<pub-id pub-id-type="pmid">32015508</pub-id></mixed-citation></ref><ref id="feb213806-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="feb213806-cit-0002">
<string-name>
<surname>Gralinski</surname>
<given-names>LE</given-names>
</string-name> and <string-name>
<surname>Menachery</surname>
<given-names>VD</given-names>
</string-name> (<year>2020</year>) <article-title>Return of the Coronavirus: 2019&#x02010;nCoV</article-title>. <source xml:lang="en">Viruses</source>, <volume>12</volume>, <fpage>135</fpage>
<pub-id pub-id-type="doi">10.3390/v12020135</pub-id>
</mixed-citation></ref><ref id="feb213806-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="feb213806-cit-0003">
<string-name>
<surname>Lu</surname>
<given-names>H</given-names>
</string-name>. (<year>2020</year>) <article-title>Drug treatment options for the 2019&#x02010;new coronavirus (2019&#x02010;nCoV)</article-title>. <source xml:lang="en">BioSci Trends</source>
<volume>14</volume>, <fpage>69</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">31996494</pub-id></mixed-citation></ref><ref id="feb213806-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="feb213806-cit-0004">
<string-name>
<surname>Wang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Zhong</surname>
<given-names>W</given-names>
</string-name> and <string-name>
<surname>Xiao</surname>
<given-names>G</given-names>
</string-name> (<year>2020</year>) <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019&#x02010;nCoV) in vitro</article-title>. <source xml:lang="en">Cell Res</source>
<volume>30</volume>, <fpage>269</fpage>&#x02013;<lpage>271</lpage>.<pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="feb213806-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="feb213806-cit-0005">
<string-name>
<surname>Gao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tian</surname>
<given-names>Z</given-names>
</string-name> and <string-name>
<surname>Yang</surname>
<given-names>X</given-names>
</string-name> (<year>2020</year>) <article-title>Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID&#x02010;19 associated pneumonia in clinical studies</article-title>. <source xml:lang="en">BioSci Trends</source>
<volume>14</volume>, <fpage>72</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">32074550</pub-id></mixed-citation></ref><ref id="feb213806-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="feb213806-cit-0006">
<string-name>
<surname>Fan</surname>
<given-names>HH</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>LQ</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>WL</given-names>
</string-name>, <string-name>
<surname>An</surname>
<given-names>XP</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>ZD</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>XQ</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>LH</given-names>
</string-name> and <string-name>
<surname>Tong</surname>
<given-names>YG</given-names>
</string-name> (<year>2020</year>) <article-title>Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019&#x02010;novel coronavirus (2019&#x02010;nCoV) related coronavirus model</article-title>. <source xml:lang="en">Chin Med J (Engl)</source>. <volume>133</volume>: <fpage>1051</fpage>&#x02013;<lpage>1056</lpage>.<pub-id pub-id-type="pmid">32149769</pub-id></mixed-citation></ref><ref id="feb213806-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="feb213806-cit-0007">
<string-name>
<surname>Dong</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>S</given-names>
</string-name> and <string-name>
<surname>Gao</surname>
<given-names>J</given-names>
</string-name> (<year>2020</year>) <article-title>Discovering drugs to treat coronavirus disease 2019 (COVID&#x02010;19)</article-title>. <source xml:lang="en">Drug Discov Ther.</source>
<volume>14</volume>, <fpage>58</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">32147628</pub-id></mixed-citation></ref><ref id="feb213806-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="feb213806-cit-0008">
<string-name>
<surname>Wrapp</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Corbett</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Goldsmith</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Hsieh</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Abiona</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Graham</surname>
<given-names>BS</given-names>
</string-name> and <string-name>
<surname>McLellan</surname>
<given-names>JS</given-names>
</string-name> (<year>2020</year>) <article-title>Cryo&#x02010;EM structure of the 2019&#x02010;nCoV spike in the prefusion conformation</article-title>. <source xml:lang="en">Science</source>. <volume>367</volume>:<fpage>1260</fpage>&#x02013;<lpage>1263</lpage>.<pub-id pub-id-type="pmid">32075877</pub-id></mixed-citation></ref><ref id="feb213806-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="feb213806-cit-0009">
<string-name>
<surname>Li</surname>
<given-names>G</given-names>
</string-name> and <string-name>
<surname>De Clercq</surname>
<given-names>E</given-names>
</string-name> (<year>2020</year>) <article-title>Therapeutic options for the 2019 novel coronavirus (2019&#x02010;nCoV)</article-title>. <source xml:lang="en">Nat Rev Drug Discov</source>
<volume>19</volume>, <fpage>149</fpage>&#x02013;<lpage>150</lpage>.<pub-id pub-id-type="pmid">32127666</pub-id></mixed-citation></ref><ref id="feb213806-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="feb213806-cit-0010">
<string-name>
<surname>Ling</surname>
<given-names>CQ</given-names>
</string-name> (<year>2020</year>) <article-title>Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS&#x02010;CoV&#x02010;2)</article-title>. <source xml:lang="en">J Int Med</source>
<volume>18</volume>, <fpage>87</fpage>&#x02013;<lpage>88</lpage>.</mixed-citation></ref><ref id="feb213806-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="feb213806-cit-0011">
<string-name>
<surname>Pang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>MX</given-names>
</string-name>, <string-name>
<surname>Ang</surname>
<given-names>IYH</given-names>
</string-name>, <string-name>
<surname>Tan</surname>
<given-names>SHX</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Gutierrez</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Gwee</surname>
<given-names>SXW</given-names>
</string-name>, <string-name>
<surname>Chua</surname>
<given-names>PEY</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>Q</given-names>
</string-name>
<italic>et al</italic> (<year>2020</year>) <article-title>Potential rapid diagnostics, vaccine and therapeutics for 2019 Novel Coronavirus (2019&#x02010;nCoV): a systematic review</article-title>. <source xml:lang="en">J Clin Med</source>
<volume>9</volume>, 623</mixed-citation></ref><ref id="feb213806-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="feb213806-cit-0012">
<string-name>
<surname>de Wit</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>van Doremalen</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Falzarano</surname>
<given-names>D</given-names>
</string-name> and <string-name>
<surname>Munster</surname>
<given-names>VJ</given-names>
</string-name> (<year>2016</year>) <article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title>. <source xml:lang="en">Nat Rev Microbiol</source>
<volume>14</volume>, <fpage>523</fpage>&#x02013;<lpage>534</lpage>.<pub-id pub-id-type="pmid">27344959</pub-id></mixed-citation></ref><ref id="feb213806-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="feb213806-cit-0013">
<string-name>
<surname>Song</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Bao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Qu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>Y</given-names>
</string-name> and <string-name>
<surname>Qin</surname>
<given-names>C</given-names>
</string-name> (<year>2019</year>) <article-title>From SARS to MERS, thrusting coronaviruses into the spotlight</article-title>. <source xml:lang="en">Viruses</source>
<volume>11</volume>, <elocation-id>59</elocation-id>.</mixed-citation></ref><ref id="feb213806-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="feb213806-cit-0014">
<string-name>
<surname>Chan</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Lai</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Chu</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Tsui</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Tam</surname>
<given-names>CY</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Tse</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Que</surname>
<given-names>TL</given-names>
</string-name>, <string-name>
<surname>Peiris</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Sung</surname>
<given-names>J</given-names>
</string-name>
<italic>et al</italic> (<year>2003</year>) <article-title>Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study</article-title>. <source xml:lang="en">Hong Kong Med J</source>
<volume>9</volume>, <fpage>399</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">14660806</pub-id></mixed-citation></ref><ref id="feb213806-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="feb213806-cit-0015">
<string-name>
<surname>Chu</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>VC</given-names>
</string-name>, <string-name>
<surname>Hung</surname>
<given-names>IF</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Kao</surname>
<given-names>RY</given-names>
</string-name>, <string-name>
<surname>Poon</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Guan</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Peiris</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Yuen</surname>
<given-names>KY</given-names>
</string-name> &#x00026; <collab collab-type="authors">Group HUSS</collab>
(<year>2004</year>) <article-title>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings</article-title>. <source xml:lang="en">Thorax</source>
<volume>59</volume>, <fpage>252</fpage>&#x02013;<lpage>256</lpage>.<pub-id pub-id-type="pmid">14985565</pub-id></mixed-citation></ref><ref id="feb213806-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="feb213806-cit-0016">
<string-name>
<surname>Nguyen</surname>
<given-names>DD</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>R</given-names>
</string-name> and <string-name>
<surname>Wei</surname>
<given-names>G&#x02010;W</given-names>
</string-name>. (<year>2020</year>) <article-title>Potentially highly potent drugs for 2019&#x02010;nCoV</article-title>. <source xml:lang="en">biorxiv</source>, 2020.02.05.936013 [PREPRINT].</mixed-citation></ref><ref id="feb213806-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="feb213806-cit-0017">
<string-name>
<surname>Xu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Peng</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Mu</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name> and <string-name>
<surname>Zhu</surname>
<given-names>W</given-names>
</string-name>. (<year>2020</year>) <article-title>Nelfinavir was predicted to be a potential inhibitor of 2019&#x02010;nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation</article-title>. <source xml:lang="en">biorxiv</source>, 2020.01.27.921627 [PREPRINT].</mixed-citation></ref><ref id="feb213806-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="feb213806-cit-0018">
<string-name>
<surname>Gordon</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Tchesnokov</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>Feng</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Porter</surname>
<given-names>DP</given-names>
</string-name> and <string-name>
<surname>Gotte</surname>
<given-names>M</given-names>
</string-name> (<year>2020</year>) <article-title>The antiviral compound remdesivir potently inhibits RNA&#x02010;dependent RNA polymerase from Middle East respiratory syndrome coronavirus</article-title>. <source xml:lang="en">J Biol Chem</source>
<volume>295</volume>, <fpage>4773</fpage>&#x02013;<lpage>4779</lpage>.<pub-id pub-id-type="pmid">32094225</pub-id></mixed-citation></ref><ref id="feb213806-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="feb213806-cit-0019">
<string-name>
<surname>Ashburn</surname>
<given-names>TT</given-names>
</string-name> and <string-name>
<surname>Thor</surname>
<given-names>KB</given-names>
</string-name> (<year>2004</year>) <article-title>Drug repositioning: identifying and developing new uses for existing drugs</article-title>. <source xml:lang="en">Nat Rev Drug Discov</source>
<volume>3</volume>, <fpage>673</fpage>&#x02013;<lpage>683</lpage>.<pub-id pub-id-type="pmid">15286734</pub-id></mixed-citation></ref><ref id="feb213806-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="feb213806-cit-0020">
<string-name>
<surname>Yildirim</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Goh</surname>
<given-names>KI</given-names>
</string-name>, <string-name>
<surname>Cusick</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Barabasi</surname>
<given-names>AL</given-names>
</string-name> and <string-name>
<surname>Vidal</surname>
<given-names>M</given-names>
</string-name> (<year>2007</year>) <article-title>Drug&#x02010;target network</article-title>. <source xml:lang="en">Nat Biotechnol</source>
<volume>25</volume>, <fpage>1119</fpage>&#x02013;<lpage>1126</lpage>.<pub-id pub-id-type="pmid">17921997</pub-id></mixed-citation></ref><ref id="feb213806-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="feb213806-cit-0021">
<string-name>
<surname>Menche</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kitsak</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ghiassian</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Vidal</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Loscalzo</surname>
<given-names>J</given-names>
</string-name> and <string-name>
<surname>Barabasi</surname>
<given-names>AL</given-names>
</string-name> (<year>2015</year>) <article-title>Disease networks. Uncovering disease&#x02010;disease relationships through the incomplete interactome</article-title>. <source xml:lang="en">Science</source>
<volume>347</volume>, <fpage>1257601</fpage>.<pub-id pub-id-type="pmid">25700523</pub-id></mixed-citation></ref><ref id="feb213806-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="feb213806-cit-0022">
<string-name>
<surname>Li</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Butte</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Swamidass</surname>
<given-names>SJ</given-names>
</string-name> and <string-name>
<surname>Lu</surname>
<given-names>Z</given-names>
</string-name> (<year>2016</year>) <article-title>A survey of current trends in computational drug repositioning</article-title>. <source xml:lang="en">Brief Bioinform</source>
<volume>17</volume>, <fpage>2</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">25832646</pub-id></mixed-citation></ref><ref id="feb213806-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="feb213806-cit-0023">
<string-name>
<surname>Pushpakom</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Iorio</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Eyers</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Escott</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Hopper</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wells</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Doig</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Guilliams</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Latimer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>McNamee</surname>
<given-names>C</given-names>
</string-name>
<italic>et al</italic> (<year>2019</year>) <article-title>Drug repurposing: progress, challenges and recommendations</article-title>. <source xml:lang="en">Nat Rev Drug Discov</source>
<volume>18</volume>, <fpage>41</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">30310233</pub-id></mixed-citation></ref><ref id="feb213806-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="feb213806-cit-0024">
<string-name>
<surname>Masoudi&#x02010;Sobhanzadeh</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Omidi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Amanlou</surname>
<given-names>M</given-names>
</string-name> and <string-name>
<surname>Masoudi&#x02010;Nejad</surname>
<given-names>A</given-names>
</string-name> (<year>2020</year>) <article-title>Drug databases and their contributions to drug repurposing</article-title>. <source xml:lang="en">Genomics</source>
<volume>112</volume>, <fpage>1087</fpage>&#x02013;<lpage>1095</lpage>.<pub-id pub-id-type="pmid">31226485</pub-id></mixed-citation></ref><ref id="feb213806-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="feb213806-cit-0025">
<string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Curth</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Drosten</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sauerhering</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rox</surname>
<given-names>K</given-names>
</string-name> and <string-name>
<surname>Hilgenfeld</surname>
<given-names>R</given-names>
</string-name> (<year>2020</year>) <article-title>Crystal structure of SARS&#x02010;CoV&#x02010;2 main protease provides a basis for design of improved &#x003b1;&#x02010;ketoamide inhibitors</article-title>. <source xml:lang="en">Science</source>
<fpage>eabb3405</fpage>.</mixed-citation></ref><ref id="feb213806-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="feb213806-cit-0026">
<string-name>
<surname>O'Leary</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Wright</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Brister</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Ciufo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Haddad</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>McVeigh</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Rajput</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Robbertse</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Smith&#x02010;White</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ako&#x02010;Adjei</surname>
<given-names>D</given-names>
</string-name>
<italic>et al</italic> (<year>2016</year>) <article-title>Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation</article-title>. <source xml:lang="en">Nucleic Acids Res</source>
<volume>44</volume>, <fpage>D733</fpage>&#x02013;<lpage>D745</lpage>.<pub-id pub-id-type="pmid">26553804</pub-id></mixed-citation></ref><ref id="feb213806-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="feb213806-cit-0027">
<string-name>
<surname>Berman</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Henrick</surname>
<given-names>K</given-names>
</string-name> and <string-name>
<surname>Nakamura</surname>
<given-names>H</given-names>
</string-name> (<year>2003</year>) <article-title>Announcing the worldwide Protein Data Bank</article-title>. <source xml:lang="en">Nat Struct Biol</source>
<volume>10</volume>, <fpage>980</fpage>.<pub-id pub-id-type="pmid">14634627</pub-id></mixed-citation></ref><ref id="feb213806-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="feb213806-cit-0028">
<string-name>
<surname>Altschul</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>Gish</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Myers</surname>
<given-names>EW</given-names>
</string-name> and <string-name>
<surname>Lipman</surname>
<given-names>DJ</given-names>
</string-name> (<year>1990</year>) <article-title>Basic local alignment search tool</article-title>. <source xml:lang="en">J Mol Biol</source>
<volume>215</volume>, <fpage>403</fpage>&#x02013;<lpage>410</lpage>.<pub-id pub-id-type="pmid">2231712</pub-id></mixed-citation></ref><ref id="feb213806-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="feb213806-cit-0029">
<string-name>
<surname>Webb</surname>
<given-names>B</given-names>
</string-name> and <string-name>
<surname>Sali</surname>
<given-names>A</given-names>
</string-name>. (<year>2014</year>) <article-title>Comparative protein structure modeling Using MODELLER</article-title>. <source xml:lang="en">Curr Protoc Bioinformatics</source>
<volume>47</volume>, 5 6 1&#x02013;5 6 32.</mixed-citation></ref><ref id="feb213806-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="feb213806-cit-0030">
<string-name>
<surname>Adams</surname>
<given-names>PD</given-names>
</string-name>, <string-name>
<surname>Afonine</surname>
<given-names>PV</given-names>
</string-name>, <string-name>
<surname>Bunkoczi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>VB</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>IW</given-names>
</string-name>, <string-name>
<surname>Echols</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Headd</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Hung</surname>
<given-names>LW</given-names>
</string-name>, <string-name>
<surname>Kapral</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Grosse&#x02010;Kunstleve</surname>
<given-names>RW</given-names>
</string-name>
<italic>et al</italic> (<year>2010</year>) <article-title>PHENIX: a comprehensive python&#x02010;based system for macromolecular structure solution</article-title>. <source xml:lang="en">Acta Crystallogr D Biol Crystallogr</source>
<volume>66</volume>, <fpage>213</fpage>&#x02013;<lpage>221</lpage>.<pub-id pub-id-type="pmid">20124702</pub-id></mixed-citation></ref><ref id="feb213806-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="feb213806-cit-0031">
<string-name>
<surname>Emsley</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lohkamp</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>WG</given-names>
</string-name> and <string-name>
<surname>Cowtan</surname>
<given-names>K</given-names>
</string-name> (<year>2010</year>) <article-title>Features and development of Coot</article-title>. <source xml:lang="en">Acta Crystallogr D Biol Crystallogr</source>
<volume>66</volume>, <fpage>486</fpage>&#x02013;<lpage>501</lpage>.<pub-id pub-id-type="pmid">20383002</pub-id></mixed-citation></ref><ref id="feb213806-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="feb213806-cit-0032">
<string-name>
<surname>Williams</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Headd</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Moriarty</surname>
<given-names>NW</given-names>
</string-name>, <string-name>
<surname>Prisant</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Videau</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Deis</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Verma</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Keedy</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Hintze</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>VB</given-names>
</string-name>
<italic>et al</italic> (<year>2017</year>) <article-title>MolProbity: More and better reference data for improved all&#x02010;atom structure validation</article-title>. <source xml:lang="en">Protein Sci</source>
<volume>27</volume>, <fpage>293</fpage>&#x02013;<lpage>315</lpage>.<pub-id pub-id-type="pmid">29067766</pub-id></mixed-citation></ref><ref id="feb213806-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="feb213806-cit-0033">
<string-name>
<surname>Kanehisa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Goto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sato</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Furumichi</surname>
<given-names>M</given-names>
</string-name> and <string-name>
<surname>Tanabe</surname>
<given-names>M</given-names>
</string-name> (<year>2012</year>) <article-title>KEGG for integration and interpretation of large&#x02010;scale molecular data sets</article-title>. <source xml:lang="en">Nucleic Acids Res</source>
<volume>40</volume>, <fpage>D109</fpage>&#x02013;<lpage>D114</lpage>.<pub-id pub-id-type="pmid">22080510</pub-id></mixed-citation></ref><ref id="feb213806-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="feb213806-cit-0034">
<string-name>
<surname>Wishart</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Feunang</surname>
<given-names>YD</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Lo</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Marcu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Grant</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Sajed</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sayeeda</surname>
<given-names>Z</given-names>
</string-name>
<italic>et al</italic> (<year>2018</year>) <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source xml:lang="en">Nucleic Acids Res</source>
<volume>46</volume>, <fpage>D1074</fpage>&#x02013;<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation></ref><ref id="feb213806-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="feb213806-cit-0035">
<string-name>
<surname>Afendi</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Okada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yamazaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hirai&#x02010;Morita</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ikeda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Altaf&#x02010;Ul&#x02010;Amin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Darusman</surname>
<given-names>LK</given-names>
</string-name>
<italic>et al</italic> (<year>2012</year>) <article-title>KNApSAcK family databases: integrated metabolite&#x02010;plant species databases for multifaceted plant research</article-title>. <source xml:lang="en">Plant Cell Physiol</source>
<volume>53</volume>, <fpage>e1</fpage>.<pub-id pub-id-type="pmid">22123792</pub-id></mixed-citation></ref><ref id="feb213806-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="feb213806-cit-0036">
<string-name>
<surname>Saito</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Takemura</surname>
<given-names>N</given-names>
</string-name> and <string-name>
<surname>Shirai</surname>
<given-names>T</given-names>
</string-name> (<year>2012</year>) <article-title>Classification of ligand molecules in PDB with fast heuristic graph match algorithm COMPLIG</article-title>. <source xml:lang="en">J Mol Biol</source>
<volume>424</volume>, <fpage>379</fpage>&#x02013;<lpage>390</lpage>.<pub-id pub-id-type="pmid">23041414</pub-id></mixed-citation></ref><ref id="feb213806-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="feb213806-cit-0037">
<string-name>
<surname>Mills</surname>
<given-names>JE</given-names>
</string-name> and <string-name>
<surname>Dean</surname>
<given-names>PM</given-names>
</string-name> (<year>1996</year>) <article-title>Three&#x02010;dimensional hydrogen&#x02010;bond geometry and probability information from a crystal survey</article-title>. <source xml:lang="en">J Comput Aided Mol Des</source>
<volume>10</volume>, <fpage>607</fpage>&#x02013;<lpage>622</lpage>.<pub-id pub-id-type="pmid">9007693</pub-id></mixed-citation></ref><ref id="feb213806-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="feb213806-cit-0038">
<string-name>
<surname>Pettersen</surname>
<given-names>EF</given-names>
</string-name>, <string-name>
<surname>Goddard</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Couch</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Greenblatt</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Meng</surname>
<given-names>EC</given-names>
</string-name> and <string-name>
<surname>Ferrin</surname>
<given-names>TE</given-names>
</string-name> (<year>2004</year>) <article-title>UCSF Chimera&#x02013;a visualization system for exploratory research and analysis</article-title>. <source xml:lang="en">J Comput Chem</source>
<volume>25</volume>, <fpage>1605</fpage>&#x02013;<lpage>1612</lpage>.<pub-id pub-id-type="pmid">15264254</pub-id></mixed-citation></ref><ref id="feb213806-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="feb213806-cit-0039">
<string-name>
<surname>Neudert</surname>
<given-names>G</given-names>
</string-name> and <string-name>
<surname>Klebe</surname>
<given-names>G</given-names>
</string-name> (<year>2011</year>) <article-title>DSX: a knowledge&#x02010;based scoring function for the assessment of protein&#x02010;ligand complexes</article-title>. <source xml:lang="en">J Chem Inf Model</source>
<volume>51</volume>, <fpage>2731</fpage>&#x02013;<lpage>2745</lpage>.<pub-id pub-id-type="pmid">21863864</pub-id></mixed-citation></ref><ref id="feb213806-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="feb213806-cit-0040">
<string-name>
<surname>Weiss</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Hughes</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Bonilla</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Turner</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Leibowitz</surname>
<given-names>JL</given-names>
</string-name> and <string-name>
<surname>Denison</surname>
<given-names>MR</given-names>
</string-name> (<year>1994</year>) <article-title>Coronavirus polyprotein processing</article-title>. <source xml:lang="en">Arch Virol Suppl</source>
<volume>9</volume>, <fpage>349</fpage>&#x02013;<lpage>358</lpage>.<pub-id pub-id-type="pmid">8032266</pub-id></mixed-citation></ref><ref id="feb213806-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="feb213806-cit-0041">
<string-name>
<surname>Hirokawa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Boon&#x02010;Chieng</surname>
<given-names>S</given-names>
</string-name> and <string-name>
<surname>Mitaku</surname>
<given-names>S</given-names>
</string-name> (<year>1998</year>) <article-title>SOSUI: classification and secondary structure prediction system for membrane proteins</article-title>. <source xml:lang="en">Bioinformatics</source>
<volume>14</volume>, <fpage>378</fpage>&#x02013;<lpage>379</lpage>.<pub-id pub-id-type="pmid">9632836</pub-id></mixed-citation></ref><ref id="feb213806-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="feb213806-cit-0042">
<string-name>
<surname>Dias</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Urban</surname>
<given-names>S</given-names>
</string-name> and <string-name>
<surname>Roessner</surname>
<given-names>U</given-names>
</string-name> (<year>2012</year>) <article-title>A historical overview of natural products in drug discovery</article-title>. <source xml:lang="en">Metabolites</source>
<volume>2</volume>, <fpage>303</fpage>&#x02013;<lpage>336</lpage>.<pub-id pub-id-type="pmid">24957513</pub-id></mixed-citation></ref><ref id="feb213806-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="feb213806-cit-0043">
<string-name>
<surname>Mushtaq</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Abbasi</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Uzair</surname>
<given-names>B</given-names>
</string-name> and <string-name>
<surname>Abbasi</surname>
<given-names>R</given-names>
</string-name> (<year>2018</year>) <article-title>Natural products as reservoirs of novel therapeutic agents</article-title>. <source xml:lang="en">EXCLI J</source>
<volume>17</volume>, <fpage>420</fpage>&#x02013;<lpage>451</lpage>.<pub-id pub-id-type="pmid">29805348</pub-id></mixed-citation></ref><ref id="feb213806-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="feb213806-cit-0044">
<string-name>
<surname>Thiel</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Ivanov</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Putics</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hertzig</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Schelle</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Bayer</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Weissbrich</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Snijder</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Rabenau</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Doerr</surname>
<given-names>HW</given-names>
</string-name>
<italic>et al</italic> (<year>2003</year>) <article-title>Mechanisms and enzymes involved in SARS coronavirus genome expression</article-title>. <source xml:lang="en">J Gen Virol</source>
<volume>84</volume>, <fpage>2305</fpage>&#x02013;<lpage>2315</lpage>.<pub-id pub-id-type="pmid">12917450</pub-id></mixed-citation></ref><ref id="feb213806-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="feb213806-cit-0045">
<string-name>
<surname>Lee</surname>
<given-names>TW</given-names>
</string-name>, <string-name>
<surname>Cherney</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>James</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Powers</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Eltis</surname>
<given-names>LD</given-names>
</string-name> and <string-name>
<surname>James</surname>
<given-names>MN</given-names>
</string-name> (<year>2007</year>) <article-title>Crystal structures reveal an induced&#x02010;fit binding of a substrate&#x02010;like Aza&#x02010;peptide epoxide to SARS coronavirus main peptidase</article-title>. <source xml:lang="en">J Mol Biol</source>
<volume>366</volume>, <fpage>916</fpage>&#x02013;<lpage>932</lpage>.<pub-id pub-id-type="pmid">17196984</pub-id></mixed-citation></ref><ref id="feb213806-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="feb213806-cit-0046">
<string-name>
<surname>Akaji</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Konno</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Mitsui</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Teruya</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Shimamoto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hattori</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ozaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kusunoki</surname>
<given-names>M</given-names>
</string-name> and <string-name>
<surname>Sanjoh</surname>
<given-names>A</given-names>
</string-name> (<year>2011</year>) <article-title>Structure&#x02010;based design, synthesis, and evaluation of peptide&#x02010;mimetic SARS 3CL protease inhibitors</article-title>. <source xml:lang="en">J Med Chem</source>
<volume>54</volume>, <fpage>7962</fpage>&#x02013;<lpage>7973</lpage>.<pub-id pub-id-type="pmid">22014094</pub-id></mixed-citation></ref><ref id="feb213806-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="feb213806-cit-0047">
<string-name>
<surname>Zhu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>George</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Al&#x02010;Gharabli</surname>
<given-names>SI</given-names>
</string-name>, <string-name>
<surname>Rademann</surname>
<given-names>J</given-names>
</string-name> and <string-name>
<surname>Hilgenfeld</surname>
<given-names>R</given-names>
</string-name> (<year>2011</year>) <article-title>Peptide aldehyde inhibitors challenge the substrate specificity of the SARS&#x02010;coronavirus main protease</article-title>. <source xml:lang="en">Antiviral Res</source>
<volume>92</volume>, <fpage>204</fpage>&#x02013;<lpage>212</lpage>.<pub-id pub-id-type="pmid">21854807</pub-id></mixed-citation></ref><ref id="feb213806-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="feb213806-cit-0048">
<string-name>
<surname>Chuck</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ke</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Wan</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Chow</surname>
<given-names>HF</given-names>
</string-name> and <string-name>
<surname>Wong</surname>
<given-names>KB</given-names>
</string-name> (<year>2013</year>) <article-title>Design, synthesis and crystallographic analysis of nitrile&#x02010;based broad&#x02010;spectrum peptidomimetic inhibitors for coronavirus 3C&#x02010;like proteases</article-title>. <source xml:lang="en">Eur J Med Chem</source>
<volume>59</volume>, <fpage>1</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">23202846</pub-id></mixed-citation></ref><ref id="feb213806-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="feb213806-cit-0049">
<string-name>
<surname>Kuhn</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Voorhees</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Strader</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Shenk</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Demo</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>van Leeuwen</surname>
<given-names>FW</given-names>
</string-name>, <string-name>
<surname>Chanan&#x02010;Khan</surname>
<given-names>AA</given-names>
</string-name> and <italic>et al</italic> (<year>2007</year>) <article-title>Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin&#x02010;proteasome pathway, against preclinical models of multiple myeloma</article-title>. <source xml:lang="en">Blood</source>
<volume>110</volume>, <fpage>3281</fpage>&#x02013;<lpage>3290</lpage>.<pub-id pub-id-type="pmid">17591945</pub-id></mixed-citation></ref><ref id="feb213806-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="feb213806-cit-0050">
<string-name>
<surname>Kortuem</surname>
<given-names>KM</given-names>
</string-name> and <string-name>
<surname>Stewart</surname>
<given-names>AK</given-names>
</string-name> (<year>2013</year>) <article-title>Carfilzomib</article-title>. <source xml:lang="en">Blood</source>
<volume>121</volume>, <fpage>893</fpage>&#x02013;<lpage>897</lpage>.<pub-id pub-id-type="pmid">23393020</pub-id></mixed-citation></ref><ref id="feb213806-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="feb213806-cit-0051">
<string-name>
<surname>Li</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Vasilieva</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Sui</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Berne</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Somasundaran</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sullivan</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Luzuriaga</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Greenough</surname>
<given-names>TC</given-names>
</string-name>
<italic>et al</italic> (<year>2003</year>) <article-title>Angiotensin&#x02010;converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title>. <source xml:lang="en">Nature</source>
<volume>426</volume>, <fpage>450</fpage>&#x02013;<lpage>454</lpage>.<pub-id pub-id-type="pmid">14647384</pub-id></mixed-citation></ref><ref id="feb213806-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="feb213806-cit-0052">
<string-name>
<surname>Natesh</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schwager</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Sturrock</surname>
<given-names>ED</given-names>
</string-name> and <string-name>
<surname>Acharya</surname>
<given-names>KR</given-names>
</string-name> (<year>2003</year>) <article-title>Crystal structure of the human angiotensin&#x02010;converting enzyme&#x02010;lisinopril complex</article-title>. <source xml:lang="en">Nature</source>
<volume>421</volume>, <fpage>551</fpage>&#x02013;<lpage>554</lpage>.<pub-id pub-id-type="pmid">12540854</pub-id></mixed-citation></ref><ref id="feb213806-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="feb213806-cit-0053">
<string-name>
<surname>Natesh</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schwager</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Evans</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Sturrock</surname>
<given-names>ED</given-names>
</string-name> and <string-name>
<surname>Acharya</surname>
<given-names>KR</given-names>
</string-name> (<year>2004</year>) <article-title>Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I&#x02010;converting enzyme</article-title>. <source xml:lang="en">Biochemistry</source>
<volume>43</volume>, <fpage>8718</fpage>&#x02013;<lpage>8724</lpage>.<pub-id pub-id-type="pmid">15236580</pub-id></mixed-citation></ref><ref id="feb213806-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="feb213806-cit-0054">
<string-name>
<surname>Yates</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Masuyer</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Schwager</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Akif</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sturrock</surname>
<given-names>ED</given-names>
</string-name> and <string-name>
<surname>Acharya</surname>
<given-names>KR</given-names>
</string-name> (<year>2014</year>) <article-title>Molecular and thermodynamic mechanisms of the chloride&#x02010;dependent human angiotensin&#x02010;I&#x02010;converting enzyme (ACE)</article-title>. <source xml:lang="en">J Biol Chem</source>
<volume>289</volume>, <fpage>1798</fpage>&#x02013;<lpage>1814</lpage>.<pub-id pub-id-type="pmid">24297181</pub-id></mixed-citation></ref><ref id="feb213806-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="feb213806-cit-0055">
<string-name>
<surname>Brunner</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Waeber</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wauters</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Turin</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>McKinstry</surname>
<given-names>D</given-names>
</string-name> and <string-name>
<surname>Gavras</surname>
<given-names>H</given-names>
</string-name> (<year>1978</year>) <article-title>Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure</article-title>. <source xml:lang="en">Lancet</source>
<volume>2</volume>, <fpage>704</fpage>&#x02013;<lpage>707</lpage>.<pub-id pub-id-type="pmid">80634</pub-id></mixed-citation></ref><ref id="feb213806-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="feb213806-cit-0056">
<string-name>
<surname>Gross</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Sweet</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Ulm</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Backlund</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Weitz</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bohn</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Wenger</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Vassil</surname>
<given-names>TC</given-names>
</string-name> and <string-name>
<surname>Stone</surname>
<given-names>CA</given-names>
</string-name> (<year>1981</year>) <article-title>Effect of N&#x02010;[(S)&#x02010;1&#x02010;carboxy&#x02010;3&#x02010;phenylpropyl]&#x02010;L&#x02010;Ala&#x02010;L&#x02010;Pro and its ethyl ester (MK&#x02010;421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo</article-title>. <source xml:lang="en">J Pharmacol Exp Ther</source>
<volume>216</volume>, <fpage>552</fpage>&#x02013;<lpage>557</lpage>.<pub-id pub-id-type="pmid">6259322</pub-id></mixed-citation></ref><ref id="feb213806-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="feb213806-cit-0057">
<string-name>
<surname>Brunner</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Desponds</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Biollaz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Keller</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Ferber</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gavras</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Brunner</surname>
<given-names>HR</given-names>
</string-name> and <string-name>
<surname>Schelling</surname>
<given-names>JL</given-names>
</string-name> (<year>1981</year>) <article-title>Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects</article-title>. <source xml:lang="en">Br J Clin Pharmacol</source>
<volume>11</volume>, <fpage>461</fpage>&#x02013;<lpage>467</lpage>.<pub-id pub-id-type="pmid">6268131</pub-id></mixed-citation></ref><ref id="feb213806-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="feb213806-cit-0058">
<string-name>
<surname>Ondetti</surname>
<given-names>MA</given-names>
</string-name> (<year>1994</year>) <article-title>From peptides to peptidases: a chronicle of drug discovery</article-title>. <source xml:lang="en">Annu Rev Pharmacol Toxicol</source>
<volume>34</volume>, <fpage>1</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">8042846</pub-id></mixed-citation></ref><ref id="feb213806-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="feb213806-cit-0059">
<string-name>
<surname>Towler</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Staker</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Prasad</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Menon</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Parsons</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ryan</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Dales</surname>
<given-names>NA</given-names>
</string-name>
<italic>et al</italic> (<year>2004</year>) <article-title>ACE2 X&#x02010;ray structures reveal a large hinge&#x02010;bending motion important for inhibitor binding and catalysis</article-title>. <source xml:lang="en">J Biol Chem</source>
<volume>279</volume>, <fpage>17996</fpage>&#x02013;<lpage>18007</lpage>.<pub-id pub-id-type="pmid">14754895</pub-id></mixed-citation></ref><ref id="feb213806-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="feb213806-cit-0060">
<string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Cai</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Pan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xiang</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Tien</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ahola</surname>
<given-names>T</given-names>
</string-name> and <string-name>
<surname>Guo</surname>
<given-names>D</given-names>
</string-name> (<year>2009</year>) <article-title>Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase</article-title>. <source xml:lang="en">Proc Natl Acad Sci U S A</source>
<volume>106</volume>, <fpage>3484</fpage>&#x02013;<lpage>3489</lpage>.<pub-id pub-id-type="pmid">19208801</pub-id></mixed-citation></ref><ref id="feb213806-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="feb213806-cit-0061">
<string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ke</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Tien</surname>
<given-names>P</given-names>
</string-name>
<italic>et al</italic> (<year>2011</year>) <article-title>Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribose 2'&#x02010;O&#x02010;methylation by nsp16/nsp10 protein complex</article-title>. <source xml:lang="en">PLoS Pathog</source>
<volume>7</volume>, <elocation-id>e1002294</elocation-id>.<pub-id pub-id-type="pmid">22022266</pub-id></mixed-citation></ref><ref id="feb213806-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="feb213806-cit-0062">
<string-name>
<surname>Decroly</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Debarnot</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ferron</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Bouvet</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Coutard</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Imbert</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Gluais</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Papageorgiou</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Sharff</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bricogne</surname>
<given-names>G</given-names>
</string-name>
<italic>et al</italic> (<year>2011</year>) <article-title>Crystal structure and functional analysis of the SARS&#x02010;coronavirus RNA cap 2'&#x02010;O&#x02010;methyltransferase nsp10/nsp16 complex</article-title>. <source xml:lang="en">PLoS Pathog</source>
<volume>7</volume>, <elocation-id>e1002059</elocation-id>.<pub-id pub-id-type="pmid">21637813</pub-id></mixed-citation></ref><ref id="feb213806-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="feb213806-cit-0063">
<string-name>
<surname>Ma</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Shaw</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Lou</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>R</given-names>
</string-name> and <string-name>
<surname>Rao</surname>
<given-names>Z</given-names>
</string-name> (<year>2015</year>) <article-title>Structural basis and functional analysis of the SARS coronavirus nsp14&#x02010;nsp10 complex</article-title>. <source xml:lang="en">Proc Natl Acad Sci U S A</source>
<volume>112</volume>, <fpage>9436</fpage>&#x02013;<lpage>9441</lpage>.<pub-id pub-id-type="pmid">26159422</pub-id></mixed-citation></ref><ref id="feb213806-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="feb213806-cit-0064">
<string-name>
<surname>Sharma</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gerbarg</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bottiglieri</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Massoumi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Carpenter</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Lavretsky</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Muskin</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Mischoulon</surname>
<given-names>D</given-names>
</string-name> &#x00026; <collab collab-type="authors">as Work Group of the American Psychiatric Association Council on, R</collab>
(<year>2017</year>) <article-title>S&#x02010;Adenosylmethionine (SAMe) for neuropsychiatric disorders: a clinician&#x02010;oriented review of research</article-title>. <source xml:lang="en">J Clin Psychiatry</source>
<volume>78</volume>, <fpage>e656</fpage>&#x02013;<lpage>e667</lpage>.<pub-id pub-id-type="pmid">28682528</pub-id></mixed-citation></ref><ref id="feb213806-bib-0065"><label>65</label><mixed-citation publication-type="book" id="feb213806-cit-0065">
<string-name>
<surname>Robert&#x02010;G&#x000e9;ro</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lawrence</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Blanchard</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Dodic</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Paolantonacci</surname>
<given-names>P</given-names>
</string-name> and <string-name>
<surname>Malina</surname>
<given-names>H</given-names>
</string-name> (<year>1989</year>) <chapter-title>Antileishmanial Effect of Sinefungin and its Derivatives</chapter-title> In <source xml:lang="en">Leishmaniasis NATO ASI Series (Series A: Life Sciences)</source> (<person-group person-group-type="editor"><name name-style="western"><surname>Hart</surname><given-names>DT</given-names></name></person-group>, ed). <publisher-name>Springer</publisher-name>, <publisher-loc>Boston</publisher-loc>.</mixed-citation></ref><ref id="feb213806-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="feb213806-cit-0066">
<string-name>
<surname>McCarthy</surname>
<given-names>MW</given-names>
</string-name> and <string-name>
<surname>Walsh</surname>
<given-names>TJ</given-names>
</string-name>. (<year>2018</year>) <article-title>Amino acid metabolism and transport mechanisms as potential antifungal targets</article-title>. <source xml:lang="en">Int J Mol Sci</source>
<volume>19</volume>, <elocation-id>909</elocation-id>.</mixed-citation></ref><ref id="feb213806-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="feb213806-cit-0067">
<string-name>
<surname>Kuroda</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yamagata</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nemoto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Inagaki</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tamura</surname>
<given-names>T</given-names>
</string-name> and <string-name>
<surname>Maeda</surname>
<given-names>K</given-names>
</string-name> (<year>2019</year>) <article-title>Antiviral effect of sinefungin on in vitro growth of feline herpesvirus type 1</article-title>. <source xml:lang="en">J Antibiot (Tokyo)</source>
<volume>72</volume>, <fpage>981</fpage>&#x02013;<lpage>985</lpage>.<pub-id pub-id-type="pmid">31534199</pub-id></mixed-citation></ref><ref id="feb213806-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="feb213806-cit-0068">
<string-name>
<surname>Hopkins</surname>
<given-names>AL</given-names>
</string-name> and <string-name>
<surname>Groom</surname>
<given-names>CR</given-names>
</string-name> (<year>2002</year>) <article-title>The druggable genome</article-title>. <source xml:lang="en">Nat Rev Drug Discov.</source>
<volume>1</volume>, <fpage>727</fpage>&#x02013;<lpage>730</lpage>.<pub-id pub-id-type="pmid">12209152</pub-id></mixed-citation></ref><ref id="feb213806-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="feb213806-cit-0069">
<string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yazdani</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>A</given-names>
</string-name> and <string-name>
<surname>Schapira</surname>
<given-names>M</given-names>
</string-name> (<year>2020</year>) <article-title>Structure&#x02010;based view of the druggable genome</article-title>. <source xml:lang="en">Drug Discov Today</source>
<volume>25</volume>, <fpage>561</fpage>&#x02013;<lpage>567</lpage>.<pub-id pub-id-type="pmid">32084498</pub-id></mixed-citation></ref><ref id="feb213806-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="feb213806-cit-0070">
<string-name>
<surname>Zhang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Penninger</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhong</surname>
<given-names>N</given-names>
</string-name> and <string-name>
<surname>Slutsky</surname>
<given-names>AS</given-names>
</string-name> (<year>2020</year>) <article-title>Angiotensin&#x02010;converting enzyme 2 (ACE2) as a SARS&#x02010;CoV&#x02010;2 receptor: molecular mechanisms and potential therapeutic target</article-title>. <source xml:lang="en">Intensive Care Med</source>
<volume>46</volume>, <fpage>586</fpage>&#x02013;<lpage>590</lpage>.<pub-id pub-id-type="pmid">32125455</pub-id></mixed-citation></ref><ref id="feb213806-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="feb213806-cit-0071">
<string-name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kleine&#x02010;Weber</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Schroeder</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kruger</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Herrler</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Erichsen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schiergens</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Herrler</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>NH</given-names>
</string-name>, <string-name>
<surname>Nitsche</surname>
<given-names>A</given-names>
</string-name>
<italic>et al</italic> (<year>2020</year>) <article-title>SARS&#x02010;CoV&#x02010;2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>. <source xml:lang="en">Cell</source>
<volume>181</volume>, <fpage>271</fpage>&#x02013;<lpage>280.e8</lpage>.<pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation></ref><ref id="feb213806-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="feb213806-cit-0072">
<string-name>
<surname>Bouvet</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Debarnot</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Imbert</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Selisko</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Snijder</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Canard</surname>
<given-names>B</given-names>
</string-name> and <string-name>
<surname>Decroly</surname>
<given-names>E</given-names>
</string-name> (<year>2010</year>) <article-title>In vitro reconstitution of SARS&#x02010;coronavirus mRNA cap methylation</article-title>. <source xml:lang="en">PLoS Pathog</source>
<volume>6</volume>, <elocation-id>e1000863</elocation-id>.<pub-id pub-id-type="pmid">20421945</pub-id></mixed-citation></ref><ref id="feb213806-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="feb213806-cit-0073">
<string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name> and <string-name>
<surname>Guo</surname>
<given-names>D</given-names>
</string-name> (<year>2016</year>) <article-title>Molecular mechanisms of coronavirus RNA capping and methylation</article-title>. <source xml:lang="en">Virol Sin</source>
<volume>31</volume>, <fpage>3</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">26847650</pub-id></mixed-citation></ref><ref id="feb213806-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="feb213806-cit-0074">
<string-name>
<surname>Hamil</surname>
<given-names>RL</given-names>
</string-name> and <string-name>
<surname>Hoehn</surname>
<given-names>MM</given-names>
</string-name> (<year>1973</year>) <article-title>A9145, a new adenine&#x02010;containing antifungal antibiotic. I. Discovery and isolation</article-title>. <source xml:lang="en">J Antibiot (Tokyo)</source>
<volume>26</volume>, <fpage>463</fpage>&#x02013;<lpage>465</lpage>.<pub-id pub-id-type="pmid">4792069</pub-id></mixed-citation></ref><ref id="feb213806-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="feb213806-cit-0075">
<string-name>
<surname>Peterman</surname>
<given-names>C</given-names>
</string-name> and <string-name>
<surname>Sanoski</surname>
<given-names>CA</given-names>
</string-name> (<year>2005</year>) <article-title>Tecadenoson: a novel, selective A1 adenosine receptor agonist</article-title>. <source xml:lang="en">Cardiol Rev</source>
<volume>13</volume>, <fpage>315</fpage>&#x02013;<lpage>321</lpage>.<pub-id pub-id-type="pmid">16230891</pub-id></mixed-citation></ref><ref id="feb213806-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="feb213806-cit-0076">
<string-name>
<surname>Li</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Torrejon</surname>
<given-names>KY</given-names>
</string-name>, <string-name>
<surname>Unser</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Ahmed</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Navarro</surname>
<given-names>ID</given-names>
</string-name>, <string-name>
<surname>Baumgartner</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Albers</surname>
<given-names>DS</given-names>
</string-name> and <string-name>
<surname>Stamer</surname>
<given-names>WD</given-names>
</string-name> (<year>2018</year>) <article-title>Trabodenoson, an adenosine mimetic with A1 receptor selectivity lowers intraocular pressure by increasing conventional outflow facility in mice</article-title>. <source xml:lang="en">Invest Ophthalmol Vis Sci</source>
<volume>59</volume>, <fpage>383</fpage>&#x02013;<lpage>392</lpage>.<pub-id pub-id-type="pmid">29346804</pub-id></mixed-citation></ref><ref id="feb213806-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="feb213806-cit-0077">
<string-name>
<surname>Savelieva</surname>
<given-names>I</given-names>
</string-name> and <string-name>
<surname>Camm</surname>
<given-names>J</given-names>
</string-name> (<year>2008</year>) <article-title>Anti&#x02010;arrhythmic drug therapy for atrial fibrillation: current anti&#x02010;arrhythmic drugs, investigational agents, and innovative approaches</article-title>. <source xml:lang="en">Europace</source>
<volume>10</volume>, <fpage>647</fpage>&#x02013;<lpage>665</lpage>.<pub-id pub-id-type="pmid">18515286</pub-id></mixed-citation></ref><ref id="feb213806-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="feb213806-cit-0078">
<string-name>
<surname>Bekker</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Kawabata</surname>
<given-names>T</given-names>
</string-name> and <string-name>
<surname>Kurisu</surname>
<given-names>G</given-names>
</string-name> (<year>2020</year>) <article-title>The Biological Structure Model Archive (BSM&#x02010;Arc): an archive for in silico models and simulations</article-title>. <source xml:lang="en">Biophysical Reviews</source>, doi: <pub-id pub-id-type="doi">10.1007/s12551-020-00632-5</pub-id>
</mixed-citation></ref></ref-list></back></article>